CN113683610B - A RET inhibitor, its pharmaceutical composition and its use - Google Patents

A RET inhibitor, its pharmaceutical composition and its use Download PDF

Info

Publication number
CN113683610B
CN113683610B CN202110531655.1A CN202110531655A CN113683610B CN 113683610 B CN113683610 B CN 113683610B CN 202110531655 A CN202110531655 A CN 202110531655A CN 113683610 B CN113683610 B CN 113683610B
Authority
CN
China
Prior art keywords
alkyl
mmol
compound
group
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110531655.1A
Other languages
Chinese (zh)
Other versions
CN113683610A (en
Inventor
谢洪明
罗明
张英俊
程应朝
何锦
王凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Guangdong HEC Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong HEC Pharmaceutical Co Ltd filed Critical Guangdong HEC Pharmaceutical Co Ltd
Publication of CN113683610A publication Critical patent/CN113683610A/en
Application granted granted Critical
Publication of CN113683610B publication Critical patent/CN113683610B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention belongs to the field of medicines, and relates to a novel RET inhibitor, a pharmaceutical composition thereof and application thereof. In particular, the invention relates to a compound shown in formula (I), or stereoisomers, geometric isomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the compound shown in formula (I), and a pharmaceutical composition comprising the compound, and application of the compound and the pharmaceutical composition thereof in preparing medicaments, wherein the medicaments are particularly used for treating and preventing RET related diseases and symptoms, including cancers, irritable bowel syndrome and/or pains related to the irritable bowel syndrome.

Description

RET inhibitor, pharmaceutical composition and application thereof
Technical Field
The present invention is in the field of medicaments, in particular, the present invention relates to novel compounds exhibiting a transfection-phase Rearrangement (RET) kinase inhibition, pharmaceutical compositions comprising said compounds, the use of compounds or pharmaceutical compositions thereof in the manufacture of a medicament, in particular for the treatment and prevention of RET related diseases and disorders, including cancer, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
Background
The transfection phase rearrangement (Re-arranged during transfection, RET) kinase is one of the receptor type tyrosine kinases belonging to the cadherin superfamily, which activates a number of downstream pathways involved in cell proliferation and survival.
The consequences of abnormal RET gene production (point mutations, chromosomal translocations, chromosomal inversion, gene amplification) are reported to be related to canceration. RET fusion proteins are associated with several cancers, including papillary thyroid cancers and non-small cell lung cancers. RET fusion proteins are identified as driving factors for certain cancers, which motivates the use of multi-kinase inhibitors with RET inhibiting activity to treat patients whose tumors express RET fusion proteins. Multiple kinase inhibitors such as sorafenib (Sorafenib), sunitinib, vandetanib, and pluratinib have been reported to exhibit cell proliferation inhibition (J Clin Oncol 30,2012,suppl;Abstract no:7510) on cell lines expressing KIF 5B-RET. In addition, the multi-kinase inhibitor cabotinib was reported to exhibit partial efficacy in two patients with non-small cell lung Cancer positive for RET fusion gene (Cancer discover, 3 (6), jun 2013, p.630-5). However, these drugs cannot always be administered at a level sufficient to inhibit RET due to toxicity caused by inhibition of targets other than RET. Furthermore, one of the biggest challenges in treating cancer is the ability of tumor cells to develop resistance to treatment. Kinase reactivation via mutation is a common drug resistance mechanism. When resistance occurs, the treatment options for patients are often very limited and in most cases cancer progression is not inhibited. WO 2017011776 discloses single-target RET kinase inhibitors having good preventive or therapeutic effects on RET and its mutation-related cancers. There is still a need to further develop compounds that inhibit RET and its resistant mutants to cope with cancers associated with abnormal RET genes.
Disclosure of Invention
The invention provides a novel compound for inhibiting a transfection-phase Rearrangement (RET) kinase, which has good inhibition effect on RET wild type and RET gene mutant, and has better inhibition selectivity on RET wild type and RET gene mutant compared with other kinases.
The excellent properties of certain parameters of the compounds of the present invention, such as half-life, clearance, selectivity, bioavailability, chemical stability, metabolic stability, membrane permeability, solubility, etc., can contribute to a reduction in side effects, an expansion of therapeutic index, or an improvement in tolerance, etc.
In one aspect, the invention provides a compound of formula (I), or a stereoisomer, tautomer, nitroxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of a compound of formula (I),
Wherein,
X 1、X2、X3、X4 and X 5 are each independently CR 4 or N;
y is O, NH or S;
T is a bond, alkylene, carbocyclylene, heterocyclylene, arylene, heteroarylene, alkylene-O-alkylene, alkylene-NH-alkylene, alkylene carbocyclylene, alkylene heterocyclylene, carbocyclylene alkylene, alkylene arylene, alkylene heteroarylene, arylene heteroarylene, alkylene heterocyclylene alkylene, or alkylene heteroarylene, and said T is optionally substituted with 1, 2, 3, or 4 substituents selected from D, OH, F, cl, br, I, CN, NH 2, oxo, alkyl, hydroxyalkyl, haloalkyl, carbocyclyl, heterocyclyl, alkoxy, alkoxyalkoxy, aryl, heteroaryl, and alkylamino;
E is a bond, -NR 6 -, or-O-;
Ring a is a carbocyclylene or heterocyclylene group, and the ring a is optionally substituted with 1,2, 3 or 4 substituents selected from F, cl, br, OH, oxo, NR 5R6、R5O-、R5(C＝O)NR6 -, aminoalkyl, alkyl, alkoxy, haloalkyl, hydroxyalkyl, carbocyclyl, heterocyclyl, heterocyclylalkyl and alkoxyalkyl;
Q is a bond 、-(CR3R3a)tO-、-(CR3R3a)tO(CR3R3a)f-、-(CR3R3a)f-、-(CR3R3a)t-NR6-、-(CR3R3a)t-NR6(CR3R3a)f-、-(C＝O)(CR3R3a)t-、-(C＝O)(CR3R3a)t-S(＝O)2(CR3R3a)f-、-(C＝O)(CR3R3a)t-NR6(CR3R3a)f-、-(C＝O)(CR3R3a)t-O(CR3R3a)f-、-(C＝O)NR5O(CR3R3a)f-、-S(＝O)2-NR6-(CR3R3a)t-、-(CR3R3a)f-(C＝O)-、-(CR3R3a)t-(C＝O)-NR5-(CR3R3a)t-、-S(＝O)2(CR3R3a)t-、-(CR3R3a)f-S(＝O)2(CR3R3a)t-、-S(＝O)2O-、-O(C＝O)-、-(C＝O)NR6- or-NR 6(C＝O)(CR3R3a)t -;
Each f is independently 1,2, 3 or 4;
each t is independently 0, 1, 2, 3 or 4;
M is H, D, heteroaryl, aryl, carbocyclyl, or heterocyclyl, and M is optionally substituted with 1,2, 3, or 4 substituents selected from D, F, cl, CN, OH, NR 5R6, alkyl, alkoxy, haloalkyl, hydroxyalkyl, haloalkoxy, aryl, alkoxyalkyl, oxo, alkanoyl, heterocyclyl, and cycloalkyl;
R 1 is H, D, CN, F, cl, br, alkyl or cycloalkyl, wherein each of said alkyl and cycloalkyl is independently optionally substituted with 1,2, 3 or 4 substituents selected from F, cl, br, CN, NH 2, OH and NO 2;
R 2 is H, D, alkyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, or aminoalkyl, and R 2 is optionally substituted with 1,2, 3, or 4 substituents selected from F、Cl、Br、OH、NR5R6、R5O-、R5O(C＝O)-、R5(C＝O)-、NR5R6(C＝O)NR5-、R5S(＝O)2-、NO2、CN、CF3、 alkyl, alkoxy, and cycloalkyl;
Each R 3 and R 3a is independently OH, F, H, D, CN, cl, br, NH 2, hydroxyalkyl, alkyl, alkylamino, alkoxy, haloalkoxy, cycloalkyl, haloalkyl, cycloalkylalkyl, aryl or heteroaryl;
Or R 3、R3a and the same carbon atom to which it is attached form a carbocyclic or heterocyclic ring;
Each R 4 is independently H, D, alkyl, F, cl, br, or alkoxy, wherein the alkyl and alkoxy groups may independently be optionally substituted with 1, 2, 3, or 4 substituents selected from F, cl, br, CN, NH 2, OH, and NO 2;
Each R 5 is independently H, D, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxyalkyl, aryloxyalkyl, aminoalkyl, carbocyclylalkyl, or heterocyclylalkyl, and R 5 is optionally substituted with 1,2, 3, or 4 substituents selected from F, cl, br, OH, NH 2, alkyl, alkynyl, alkylsulfonyl, alkoxy, aryl, and heteroaryl, and
Each R 6 is independently H or alkyl.
In some embodiments, T is a bond, C 1-6 alkylene, 3-12 carbocyclylene, 3-12 heterocyclylene, C 6-10 arylene, 5-10 heteroarylene, C 1-6 alkylene-O-C 1-6 alkylene, C 1-6 alkylene-NH-C 1-6 alkylene, C 1-6 alkylene- (3-12 membered carbocyclylene), C 1-6 alkylene- (3-12 membered heterocyclylene), (3-12 membered carbocyclylene) -C 1-6 alkylene, (3-12 membered heterocyclylene) -C 1-6 alkylene, C 1-6 alkylene C 6-10 arylene, C 1-6 alkylene- (5-10 membered heteroarylene), C 6-10 arylene C 1-6 alkylene, (5-10 membered heteroarylene) -C 1-6 alkylene, C 1-6 alkylene- (3-12 membered heterocyclylene) -C 1-6 alkylene or C 1-6 alkylene- (5-10 membered heteroarylene) -C 1-6 alkylene, and said T is optionally substituted with 1, 2. 3 or 4 are selected from D, OH, F, cl, br, I, CN, NH 2, oxo, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkoxy, C 6-10 aryl, Substituents for 5-to 10-membered heteroaryl and C 1-6 -alkylamino.
In some embodiments, T is a bond, C 1-6 alkylene, 3-6 carbocyclylene, 3-6 heterocyclylene, C 6-10 arylene, 5-10 heteroarylene, C 1-4 alkylene-O-C 1-4 alkylene, c 1-4 alkylene-NH-C 1-4 alkylene, C 1-4 alkylene- (3-6 membered carbocyclylene), C 1-4 alkylene- (3-6 membered heterocyclylene), (3-6 membered carbocyclylene) -C 1-4 alkylene, (3-6 membered heterocyclylene) -C 1-4 alkylene, C 1-4 alkylene C 6-10 arylene, C 6-10 arylene C 1-4 alkylene, (5-6 membered heteroarylene) -C 1-4 alkylene, C 1-4 alkylene- (5-6 membered heteroarylene), C 1-4 alkylene- (3-6 membered heterocyclylene) -C 1-4 alkylene or C 1-4 alkylene- (5-6 membered heteroarylene) -C 1-4 alkylene, and said T is optionally substituted with 1, 2. 3 or 4 are selected from D, OH, F, cl, br, I, CN, NH 2, oxo, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 1-4 haloalkyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, C 1-4 alkoxy, C 1-4 alkoxy C 1-4 alkoxy, C 6-10 aryl, Substituents for 5-6 membered heteroaryl and C 1-4 alkylamino.
In some embodiments, T is a bond 、-CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-CH2CH(CH3)-、-CH2CH(CH3)CH2-、-CH2C(CH3)2-、-(CH2)2CH(CH3)-、-(CH2)2OCH2-、-(CH2)2NHCH2-、-(CH2)3NHCH2-、-(CH2)2- cyclopentylene, -CH 2 -cyclopentylene, -CH 2 -cyclobutylene, - (CH 2)2 -piperidinylene), - (CH 2)2 -piperazinylene, - (CH 2)2 -piperazinylene-CH 2-、-CH2 -tetrahydropyranyl, - (CH 2)2 -tetrahydropyranyl), -CH 2 -pyridylene, cyclobutylene, cyclopentylene, azetidinylene-CH 2 -, octahydropentalene, spiro [4.4] nonane, octahydrocyclopenteno-pyrrolylene, - (CH 2)2 -octahydrocyclopenteno-pyrrolylene), - (CH 2)2 -2-azaspiro [3.4] octanyl, - (CH 2)2 -3-azabicyclo [3.1.1] heptanyl, phenylene), -CH 2 -oxazolylene-CH 2 -or-CH 2 -imidazolylene-CH 2 -, and said T is optionally substituted with 1, 2. 3 or 4 substituents selected from D, F, cl, br, I, CN, NH 2, OH, oxo, methyl, ethyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclopropylene, azetidinyl, chloromethyl, fluoromethyl, cyclohexyl, methoxymethoxy, methylamino.
In some embodiments, ring a is a 3-12 membered carbocyclylene or a 3-12 membered heterocyclylene, and the ring a is optionally substituted with 1,2,3, or 4 substituents selected from F, cl, br, OH, oxo, NR 5R6、R5O-、R5(C＝O)NR6-、C1-6 aminoalkyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, (3-12 membered heterocyclyl) -C 1-6 alkyl, and C 1-6 alkoxy C 1-6 alkyl;
Each R 5 is independently H, D, C 1-6 alkyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, C 6-10 arylC 1-6 alkyl, (5-10 membered heteroaryl) -C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 6-10 aryloxycarbonyl C 1-6 alkyl, c 1-6 aminoalkyl, (3-6 membered carbocyclyl) -C 1-6 alkyl or (3-6 membered heterocyclyl) -C 1-6 alkyl, and said R 5 is optionally substituted with 1, 2.3 or 4 are selected from F, cl, br, OH, NH 2、C1-6 alkyl, C 2-6 alkynyl, C 1-6 alkylsulfonyl, C 1-6 alkoxy, Substituted with C 6-10 aryl and 5-10 membered heteroaryl, and
R 6 is H, D or C 1-6 alkyl.
In some embodiments, ring a is of the following sub-structural formula:
Wherein each Z 1 and Z 2 is independently CH 2 or NH;
Z 4 is CH or N;
Each Z 3 and Z 5 is independently a bond, CH 2, O, S, NH, C = O, S =o, or S (=o) 2;
m is 0, 1 or 2;
n, m1 and n1 are each independently 0 or 1;
And each sub-structural formula of ring a is independently optionally substituted with 1,2,3 or 4 substituents selected from F, cl, br, OH, oxo, NR 5R6、R5O-、R5(C＝O)NR6-、C1-4 aminoalkyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, 3-6 membered heterocyclylalkyl and C 1-4 alkoxy C 1-4 alkyl;
Each R 5 is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, methoxymethyl, methoxyethyl, ethoxyethyl, phenylmethyl, phenylethyl, phenyl-n-propyl, pyridylmethyl, pyridylethyl, pyridylen-propyl, phenoxymethyl, phenoxyethyl, phenoxyn-propyl, azetidinyl, oxetanyl or tetrahydropyranyl, and said R 5 is optionally substituted with 1,2, 3 or 4 substituents selected from F、Cl、Br、OH、NH2、CH3S(＝O)2-、CH3CH2S(＝O)2-、CH(CH3)2S(＝O)2-、C(CH3)3S(＝O)2-、 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, ethynyl, methoxy, ethoxy, n-propoxy, phenyl, pyridyl, pyrazolyl and pyrimidinyl, and
Each R 6 is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl.
In some embodiments, ring a is of the following sub-structural formula:
And each substructure of ring a is independently optionally substituted with 1, 2, 3 or 4 substituents selected from F, cl, br, oxo, OH, NH 2、NHCH3、CH3 (c=o) NH-, methyl, ethyl, n-propyl, methoxy, ethoxy, isopropoxy, CF 3, hydroxymethyl, 2-hydroxyethyl, cyclopropyl, cyclohexyl, pyrrolidinyl, piperidinyl and tetrahydrofuranyl.
In some embodiments, M is H, D, 5-10 membered heteroaryl, C 6-10 aryl, 3-12 membered carbocyclyl, or 3-12 membered heterocyclyl, and M is optionally substituted with 1,2,3, or 4 substituents selected from F, cl, CN, OH, NR 5R6、C1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkoxy, C 6-10 aryl, C 1-6 alkoxy C 1-6 alkyl, oxo, C 1-6 alkanoyl, 3-7 membered heterocyclyl, and C 3-7 cycloalkyl;
Wherein each R 5 and R 6 has the definition as described herein.
In some embodiments, M is H, D, pyridinyl, pyrimidinyl, pyridazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazinyl, phenyl, cyclopentyl, cyclopropyl, cyclohexyl, cyclobutyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, morpholinyl, tetrahydrothiopyranyl, oxetanyl, 1, 2-dihydropyridinyl, 7-azabicyclo [2.2.1] heptanyl, hexahydrofuro [3,4-c ] pyrrolyl, 3-azabicyclo [3.1.0] hexanyl, octahydropyrrolo [1,2-a ] pyrazinyl, or 5-azaspiro [2.4] heptanyl, and M is optionally substituted with 1,2, 3, or 4 substituents selected from D、F、Cl、CN、OH、CF3、CHCl2、CHF2、CH2F、CF3CH2、NH2、NHCH3、CH2OH、N(CH3)2、 trifluoromethoxy, 2-trifluoroethoxy, methoxy, ethoxy, isopropoxy, tert-butoxy, methyl, ethyl, n-propyl, isopropyl, phenyl, methoxymethyl, methoxyethyl, oxo, acetyl, piperidinyl, tetrahydropyranyl, piperidinyl, and tetrahydropyranyl.
In some embodiments, R 2 is H, D, C 1-6 alkyl, C 2-6 alkynyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, (3-12 membered carbocyclyl) -C 1-6 alkyl, (3-12 membered heterocyclyl) -C 1-6 alkyl, C 1-6 alkoxyc 1-6 alkyl, C 6-10 arylc 1-6 alkyl, (5-10 membered heteroaryl) -C 1-6 alkyl, or C 1-6 aminoalkyl, and said R 2 is optionally substituted with 1, 2, 3, or 4 substituents selected from F、Cl、Br、OH、NR5R6、R5O-、R5O(C＝O)-、R5(C＝O)-、NR5R6(C＝O)NR5-、R5S(＝O)2-、NO2、CN、CF3、C1-6 alkyl, C 1-6 alkoxy, and C 3-12 cycloalkyl;
Wherein each R 5 and R 6 has the definition as described herein.
In some embodiments, R 2 is H, D, C 1-4 alkyl, C 2-4 alkynyl, 3-10 membered carbocyclyl, 3-10 membered heterocyclyl, phenyl, 5-10 membered heteroaryl, (3-10 membered carbocyclyl) -C 1-4 alkyl, (3-10 membered heterocyclyl) -C 1-4 alkyl, C 1-4 alkoxyc 1-4 alkyl, phenylc 1-4 alkyl, (5-10 membered heteroaryl) -C 1-4 alkyl, or C 1-4 aminoalkyl, and said R 2 is optionally substituted with 1,2, 3, or 4 substituents selected from F、Cl、Br、OH、NR5R6、R5O-、R5O(C＝O)-、R5(C＝O)-、NR5R6(C＝O)NR5-、R5S(＝O)2-、NO2、CN、CF3、C1-4 alkyl, C 1-4 alkoxy, and C 3-6 cycloalkyl;
Wherein each R 5 and R 6 has the definition as described herein.
In some embodiments of the present invention, in some embodiments, R 2 is H, D, methyl, ethyl, N-propyl, isopropyl, N-butyl, isobutyl, tert-butyl, N-pentyl, N-hexyl, ethynyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, spiro [4.4] nonanylmethyl, azaspiro [4.4] nonanylmethyl, bicyclo [3.3.0] octanyl, pyrrolidinyl, azetidinyl, piperidinyl, morpholinyl, azetidinylmethyl, piperidinylmethyl, morpholinylmethyl, methoxymethyl, methoxyethyl, ethoxymethyl ethoxyethyl, N-propoxymethyl, isopropoxymethyl, N-butoxymethyl, isobutoxymethyl, tert-butoxymethyl, tert-butoxyethyl, phenyl, pyridinyl, imidazolyl, pyrazolyl, pyrimidinyl, 3H-indolyl, benzimidazolyl, 3,8 a-indolizinyl, phenylmethyl, 3,8 a-indolizinylmethyl, pyridylmethyl, imidazolylmethyl, pyrazolylmethyl, pyrimidinylmethyl, 3H-indolylmethyl, benzimidazolylmethyl, NH 2CH2-、NH2(CH2)2 -or N (CH 3)2(CH2)2 -, and said R 2 is optionally substituted with 1, 2, 3 or 4 substituents selected from F、Cl、Br、OH、NH2、NO2、CN、CF3、C(CH3)3O(C＝O)-、CH3(C＝O)-、NH2(C＝O)NH-、NHCH3(C＝O)NH-、CH3S(＝O)2-、 methyl, methoxy, ethoxy, N-propoxy, isopropoxy, phenoxy, pyridyloxy, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
In some embodiments, R 1 is H, D, CN, F, cl, br, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein each of the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups is independently optionally substituted with 1,2, 3, or 4 substituents selected from F, cl, br, CN, NH 2, OH, and NO 2, and
Each R 4 is independently H, D, F, cl, br, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butylmethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or t-butoxy, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butylmethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and t-butoxy are each independently optionally substituted with 1,2, 3 or 4 substituents selected from F, cl, br, CN, NH 2, OH and NO 2.
In some embodiments, each R 3 and R 3a is independently OH, F, H, D, CN, cl, br, NH 2、C1-6 hydroxyalkyl, C 1-6 alkyl, C 1-6 alkylamino, C 1-6 alkoxy, C 1-6 haloalkoxy, C 3-7 cycloalkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl C 1-6 alkyl, C 6-10 aryl, or 5-10 membered heteroaryl;
Or R 3、R3a and the same C atom attached thereto form a 3-7 membered carbocyclic ring or a 3-7 membered heterocyclic ring.
In some embodiments, each R 3 and R 3a is independently OH, F, CF 3、CHCl2、CHF2、H、D、CN、Cl、Br、NH2, hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, methyl, ethyl, N (CH 3)2, methoxy, ethoxy, isopropoxy, t-butoxy, trifluoromethoxy, cyclopropyl, cyclopentyl, cyclopropylmethyl, cyclopentylethyl, cyclopentylmethyl, phenyl, pyridinyl, or pyrazinyl;
Or R 3、R3a and the same C atom attached thereto form cyclopentane, cyclopropane, cyclobutane, tetrahydropyran, tetrahydrofuran, piperidine or pyrrolidine.
In some embodiments, Q is a bond 、-O-、-(CH2)2O-、-(CH2)2OC(CH3)2CH2-、-CH2-、-(CH2)2-、-(CH2)3-、-CH2CH(CH3)CH2-、-CH2CH(CH3)CH2NHCH2-、-CH2N(CH3)CH2-、-(C＝O)OC(CH3)2CH2-、-(C＝O)(CH2)2S(＝O)2CH2-、-(C＝O)CH(OH)CH2-、-(C＝O)CH(OH)-、-(C＝O)CH(OH)CH2-、-(C＝O)-、-S(＝O)2-、-(C＝O)CH2CH(OH)-、-(C＝O)CH2-、-(C＝O)CH(CH2OH)-、-(C＝O)C(CH3)2-、-(C＝O)CH2NHC(CH3)2CH2-、-(C＝O)CH2CH(N(CH3)2)-、-(C＝O)(CH2)2CH(N(CH3)2)-、-(C＝O)C(CH3)2CH2-、-(C＝O)C(OH)(CH3)CH2-、-(C＝O)CH2OCH2-、-(C＝O)(CH2)3-、-(C＝O)CH(NH2)-、-(C＝O)(CH2)3N(CH3)CH2-、-(C＝O)(CH2)2-、-(C＝O)CH2CH(OH)CH2-、-(C＝O)CF2CH2-、-(C＝O)CH(OH)C(CH3)2CH2-、-(C＝O)CH2C(CH3)2-、-(C＝O)CH2C(CH3)2CH2-、-(C＝O)CH2C(CH3)(OH)CH2-、-S(＝O)2CH2-、-S(＝O)2CH2C(CH3)2CH2-、-(C＝O)CH(OCH3)-、-(C＝O)NHCH(CH2OH)(CH2)2-、-(C＝O)NH-、-(C＝O)OCH2C(CH3)2-、-(C＝O)N(CH3)-、-(C＝O)N(CH2CH2CH2CH3)-、-(C＝O)N(CH2CH3)(CH2)2-、-(C＝O)NHC(CH3)2CH2-、-(C＝O)N(CH3)(CH2)2-、-(C＝O)NHCH2CH(CH3)CH2-、-(C＝O)NHCH2-、-(C＝O)NH(CH2)2OCH2-、-(C＝O)N(CH3)CH2CH(OCH3)-、-S(＝O)2NHC(CH3)2CH2-、-CH2CH(OH)C(CH3)2CH2-、-CH(CH3)CH(OH)-、-CH2(C＝O)NHCH(CH3)CH2-、-CH2(C＝O)-、-(CH2)2(C＝O)N(CH3)CH2-、-CH2CH(OH)-、-CH2CH(OH)CH2-、-CH2CH(OH)CH(CH3)CH2-、-(C＝O)CH(N(CH3)2)-、-(C＝O)C(CH3)2)CH2OCH2-、-(C＝O)C(OCH3)(CF3)-、-(C＝O)N(CH2CH2OCH3)CH2CH(OCH3)-、-CH2CH(OCF3)-、-CH2CH(OCH(CH3)2)-、-CH2CH(OC(CH3)3)-、-CH2CF2-、-CH(CH3)-、-CH2CH(OCH3)C(CH3)2-、-CH2CH(N(CH3)2)-、-NH-、-(C＝O)NHOCH2-、-(C＝O)NHOCH2(CHOH)-、-S(＝O)2(CH2CH3)-、-S(＝O)2O-、-S(＝O)2-NHC(CH3)2-、-(CH2)2S(＝O)2-、-(CH2)3S(＝O)2CH(CH3)CH2-、-NH(C＝O)CH2-
In some embodiments, the compounds of the present invention have the structure of formula (I-1), or stereoisomers, tautomers, nitroxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the structure of formula (I-1),
Wherein,
Each Z 1a and Z 2a is independently CH or N;
Each Z 3 and Z 5 is independently a bond, CH 2, O, S, NH, C = O, S =o, or S (=o) 2;
m is 0, 1 or 2;
And is also provided with Optionally substituted with 1,2,3 or 4 substituents selected from F, cl, br, OH, oxo, NR 5R6、R5O-、R5(C＝O)NR6-、C1-4 aminoalkyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, 3-6 membered heterocyclylalkyl and C 1-4 alkoxy C 1-4 alkyl;
each R1、R2、R5、R6、X1、X2、X3、X4、X5、T、E、Q and M has the definition as described in the present invention.
In some embodiments of the present invention, in some embodiments,The structural formula is as follows: And is also provided with Independently optionally substituted with 1, 2,3 or 4 substituents selected from F, cl, br, OH, oxo, NH 2、NHCH3、CH3 (c=o) NH-, methyl, ethyl, n-propyl, methoxy, ethoxy, isopropoxy, CF 3, hydroxymethyl, 2-hydroxyethyl, cyclopropyl, cyclohexyl, pyrrolidinyl, piperidinyl and tetrahydrofuranyl.
In some embodiments, the compounds of the present invention have the structure of formula (I-2), or stereoisomers, tautomers, nitroxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the structure of formula (I-2),
Wherein,
Ring A1 is of the sub-structural formula:
z 1 and Z 2 are each independently CH or N;
And each sub-structural formula of ring A1 is independently optionally substituted with 1, 2,3 or4 substituents selected from F, cl, br, OH, oxo, NR 5R6、R5O-、R5(C＝O)NR6-、C1-4 aminoalkyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, 3-6 membered heterocyclylalkyl and C 1-4 alkoxy C 1-4 alkyl;
each R1、R2、R5、R6、X1、X2、X3、X4、X5、T、E、Q and M has the definition as described in the present invention.
In some embodiments, ring A1 is of the following sub-structural formula:
And each sub-structural formula of ring A1 is independently optionally substituted with 1, 2,3 or 4 substituents selected from F, cl, br, OH, oxo, NH 2、NHCH3、CH3 (c=o) NH-, methyl, ethyl, n-propyl, methoxy, ethoxy, isopropoxy, CF 3, hydroxymethyl, 2-hydroxyethyl, cyclopropyl, cyclohexyl, pyrrolidinyl, piperidinyl and tetrahydrofuranyl. .
In some embodiments, the compounds of the present invention have the structure of formula (I-3), or stereoisomers, tautomers, nitroxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the structure of formula (I-3),
Wherein ring A2 is
Z 1、Z2 and Z 4 are each independently CH or N;
m is 0, 1 or 2;
n, m1 and n1 are each independently 0 or 1;
And is also provided with Each independently optionally substituted with 1,2, 3 or 4 substituents selected from F, cl, br, OH, oxo, NR 5R6、R5O-、R5(C＝O)NR6-、C1-4 aminoalkyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, 3-6 membered carbocyclyl, 3-6 membered heterocyclyl, 3-6 membered heterocyclylalkyl and C 1-4 alkoxy C 1-4 alkyl;
each R1、R2、R5、R6、X1、X2、X3、X4、X5、T、E、Q and M has the definition as described in the present invention.
In some embodiments of the present invention, in some embodiments,
Ring A2 is
And each substructure of ring A2 is independently optionally substituted with 1, 2, 3 or 4 substituents selected from F, cl, br, oxo, OH, NH 2、NHCH3、CH3 (c=o) NH-, methyl, ethyl, n-propyl, methoxy, ethoxy, isopropoxy, CF 3, hydroxymethyl, 2-hydroxyethyl, cyclopropyl, cyclohexyl, pyrrolidinyl, piperidinyl and tetrahydrofuranyl.
In some embodiments, the compounds of the present invention have one of the following structures, or stereoisomers, tautomers, nitroxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof,
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention, and a pharmaceutically acceptable adjuvant.
In another aspect, the invention also provides the use of the compound of the invention or the pharmaceutical composition of the invention in the preparation of a medicament for preventing or treating RET-related diseases.
In some embodiments, the RET related disease includes cancer, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
In another aspect, the invention also provides a compound of the invention or a pharmaceutical composition of the invention for use in the prevention or treatment of RET-related disorders.
In some embodiments, the RET related disease includes cancer, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
In another aspect, the invention also provides a method of preventing or treating RET-related disorders comprising administering to a patient a therapeutically effective amount of a compound of the invention or a pharmaceutical composition thereof.
In some embodiments, the RET related disease includes cancer, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
In another aspect, the present invention relates to intermediates for preparing compounds of formula (I), (I-1), (I-2) or (I-3).
In another aspect, the present invention relates to methods for the preparation, isolation and purification of compounds of formula (I), (I-1), (I-2) or (I-3).
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention and pharmaceutically acceptable adjuvants thereof. In some embodiments, adjuvants described herein include, but are not limited to, carriers, excipients, diluents, vehicles, or combinations thereof. In some embodiments, the pharmaceutical composition may be in a liquid, solid, semi-solid, gel or spray form.
Unless otherwise indicated, all stereoisomers, geometric isomers, tautomers, nitroxides, hydrates, solvates, metabolites, salts and pharmaceutically acceptable prodrugs of the compounds of the invention are within the scope of the invention.
In particular, salts are pharmaceutically acceptable salts. The term "pharmaceutically acceptable" includes substances or compositions that must be suitable for chemical or toxicological use, in relation to the other components that make up the formulation and the mammal being treated.
The salts of the compounds of the present invention also include intermediates or intermediates of formula (I) useful in the preparation or purification of the compounds of formula (I), (I-1), (I-2) or (I-3),
Salts of isolated enantiomers of the compounds of formula (I-1), (I-2) or (I-3), but not necessarily pharmaceutically acceptable salts.
In the structures disclosed herein, when the stereochemistry of any particular chiral atom is not indicated, then all stereoisomers of that structure are contemplated as being within the present invention and are included as presently disclosed compounds. When stereochemistry is indicated by the solid wedge (solid wedge) or dashed line representing a particular configuration, then the stereoisomers of that structure are so defined and defined.
Nitrogen oxides of the compounds of the present invention are also included within the scope of the present invention. The nitrogen oxides of the compounds of the invention may be prepared by oxidizing the corresponding nitrogen-containing basic species in the presence of an acid such as acetic acid, using conventional oxidizing agents (e.g., hydrogen peroxide) at elevated temperature, or by reacting with a peracid in a suitable solvent, such as dichloromethane, ethyl acetate or methyl acetate, or 3-chloroperoxybenzoic acid in chloroform or dichloromethane.
If the compounds of the present invention are basic, the desired salts may be prepared by any suitable method provided in the literature, for example, using mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Or organic acids such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid and salicylic acid, pyronic acids such as glucuronic acid and galacturonic acid, alpha-hydroxy acids such as citric acid and tartaric acid, amino acids such as aspartic acid and glutamic acid, aromatic acids such as benzoic acid and cinnamic acid, sulfonic acids such as p-toluenesulfonic acid, ethanesulfonic acid, and the like.
If the compounds of the invention are acidic, the desired salts can be prepared by suitable methods, for example, using inorganic or organic bases, such as ammonia (primary, secondary, tertiary), alkali or alkaline earth metal hydroxides, and the like. Suitable salts include, but are not limited to, organic salts derived from amino acids such as glycine and arginine, ammonia such as primary, secondary and tertiary, and cyclic ammonia such as piperidine, morpholine and piperazine, and the like, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
Detailed description of the invention
Definitions and general terms
Reference will now be made in detail to certain embodiments of the application, examples of which are illustrated in the accompanying structural and chemical formulas. The application is intended to cover all alternatives, modifications and equivalents, which may be included within the scope of the application as defined by the appended claims. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used in the practice of the present application. The present application is in no way limited to the methods and materials described herein. In the event of one or more of the incorporated references, patents and similar materials differing from or contradictory to the present application (including but not limited to defined terms, term application, described techniques, etc.), the present application controls.
It should further be appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference in their entirety.
The term "subject" as used herein refers to an animal. Typically the animal is a mammal. The subject, for example, also refers to a primate (e.g., human, male or female), cow, sheep, goat, horse, dog, cat, rabbit, rat, mouse, fish, bird, and the like. In certain embodiments, the subject is a primate. In other embodiments, the subject is a human.
The term "patient" as used herein refers to a human (including adults and children) or other animals. In some embodiments, "patient" refers to a human.
The term "comprising" is an open-ended expression, i.e., including what is indicated by the invention, but not excluding other aspects.
"Stereoisomers" refer to compounds having the same chemical structure but different arrangements of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis/trans isomers), atropisomers, and the like. All stereoisomers or mixtures of stereoisomers of the formulae described herein are within the scope of the invention unless otherwise indicated. In addition, unless otherwise indicated, the structural formulae of the compounds described herein include enriched isotopes of one or more different atoms.
The stereochemical definitions and rules used in the present invention generally follow S.P.Parker,Ed.,McGraw-Hill Dictionary of Chemical Terms(1984)McGraw-Hill Book Company,New York;and Eliel,E.and Wilen,S.,"Stereochemistry of Organic Compounds",John Wiley&Sons,Inc.,New York,1994.
The resulting mixture of any stereoisomers may be separated into pure or substantially pure geometric isomers, enantiomers, diastereomers, e.g., by chromatography and/or fractional crystallization, depending on the differences in the physicochemical properties of the components.
The term "tautomer" or "tautomeric form" refers to structural isomers having different energies that can be interconverted by a low energy barrier (low energy barrier). If tautomerism is possible (e.g., in solution), chemical equilibrium of the tautomers can be achieved. For example, proton tautomer (protontautomer) (also known as proton transfer tautomer (prototropic tautomer)) includes interconversions by proton transfer, such as keto-enol isomerisation and imine-enamine isomerisation. Valence tautomers (valence tautomer) include interconversions by recombination of some of the bond-forming electrons. Specific examples of keto-enol tautomerism are tautomerism of pentane-2, 4-dione and 4-hydroxypent-3-en-2-one tautomer. Another example of tautomerism is phenol-ketone tautomerism. One specific example of phenol-ketone tautomerism is the interconversion of pyridin-4-ol and pyridin-4 (1H) -one tautomers. Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
The compounds of the invention, as described herein, may independently be optionally substituted with one or more substituents, such as those of the general formula above, or as exemplified by the specific examples provided herein, subclasses, and classes of compounds encompassed by the invention. It is to be understood that the terms "independently optionally substituted" or "optionally substituted" may be used interchangeably with the term "substituted or unsubstituted. In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced with a specific substituent. An optional substituent group may be substituted at each substitutable position of the group unless otherwise indicated. When more than one position in a given formula can be substituted with one or more substituents selected from a particular group, then the substituents may be the same or different at each position.
In addition, unless explicitly stated otherwise, the description as used in this disclosure is "each..and". Independently "and". Independently "can be interchanged, and is to be understood broadly as meaning that specific items expressed between the same symbols in different groups do not affect each other, or that specific items expressed between the same symbols in the same groups do not affect each other.
In the various parts of the present specification, substituents of the presently disclosed compounds are disclosed in terms of the type or scope of groups. It is specifically noted that the present invention includes each individual subcombination of the individual members of these group classes and ranges. For example, the term "C 1-6 alkyl" refers specifically to independently disclosed methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, and C 6 alkyl.
In the various parts of the invention, linking substituents are described. When the structure clearly requires a linking group, the markush variables recited for that group are understood to be linking groups. For example, if the structure requires a linking group and the markush group definition for that variable enumerates an "alkyl" or "aryl" group, it will be understood that the "alkyl" or "aryl" represents a linked alkylene group or arylene group, respectively.
The term "alkyl" denotes a saturated, straight or branched, monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, alkyl groups contain 1 to 20 carbon atoms. In one embodiment, the alkyl group contains 1 to 12 carbon atoms, in another embodiment, the alkyl group contains 1 to 6 carbon atoms, in yet another embodiment, the alkyl group contains 1 to 4 carbon atoms, and in yet another embodiment, the alkyl group contains 1 to 3 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH 3), ethyl (Et, -CH 2CH3), n-propyl (n-Pr, -CH 2CH2CH3), isopropyl (i-Pr, -CH (CH 3)2), n-butyl (n-Bu), -CH 2CH2CH2CH3), isobutyl (i-Bu, -CH 2CH(CH3)2), sec-butyl (s-Bu, -CH (CH 3)CH2CH3), tert-butyl (t-Bu), -C (CH 3)3), n-pentyl (-CH 2CH2CH2CH2CH3), 2-pentyl (-CH (CH 3)CH2CH2CH3), 3-pentyl (-CH (CH 2CH3)2), 2-methyl-2-butyl (-C (CH 3)2CH2CH3), 3-methyl-2-butyl (-CH (CH 3)CH(CH3)2), 3-methyl-1-butyl (-CH 2CH2CH(CH3)2), 2-methyl-1-butyl (-CH 2CH(CH3)CH2CH3), n-hexyl (-CH 2CH2CH2CH2CH2CH3), 2-hexyl (-CH (CH 3)CH2CH2CH2CH3), 3-hexyl (-CH (CH 2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C (CH 3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH (CH 3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH (CH 3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C (CH 3)(CH2CH3)2), 2-methyl-3-pentyl (-CH (CH 2CH3)CH(CH3)2), 2, 3-dimethyl-2-butyl (-C (CH 3)2CH(CH3)2), 3-dimethyl-2-butyl (-CH (CH 3)C(CH3)3)), n-heptyl, n-octyl, and the like.
When alkyl is a linking group, then "alkyl" represents a linked alkylene group. M is a linked alkylene group as defined herein. The term "alkylene" refers to a saturated divalent hydrocarbon group resulting from the removal of two hydrogen atoms from a saturated straight or branched hydrocarbon. Examples of alkyl groups represented as linked alkylene groups include, but are not limited to, -CH 2-、-CH2CH2-、-CH(CH3)CH2 -, and the like.
The term "alkynyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e. one carbon-carbon sp triple bond, wherein the alkynyl group may be optionally substituted with one or more substituents as described herein. In one embodiment, the alkynyl group contains 2 to 6 carbon atoms, in yet another embodiment, the alkynyl group contains 2 to 10 carbon atoms, and the alkynyl group contains 2 to 4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), propargyl (-CH 2 C≡CH), 1-propynyl (-C≡C-CH 3), and the like. When alkynyl is a linking group, and "alkynyl" is recited for this markush group definition, then "alkynyl" means a linked alkynylene group. Examples of alkynyl groups represented as linked alkynylene groups include, but are not limited to, -C.ident.C-, -CH 2C≡C-、-CH2C≡CCH2 -, and the like.
The terms "cycloalkyl" or "cycloalkane" are used interchangeably and refer to a monovalent saturated monocyclic carbocyclic ring system of 3 to 7 carbon atoms. the-CH 2 -group in the carbocycle may optionally be replaced by-C (=o) - (or- (c=o) -). In one embodiment, cycloalkyl contains 3 to 6 carbon atoms, i.e., C 3-6 cycloalkyl, and in another embodiment, cycloalkyl contains 3 to 5 carbon atoms, i.e., C 3-5 cycloalkyl. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of carbon rings in which the-CH 2 -group may be replaced by-C (=O) -include, but are not limited to, cyclopentanone, cyclobutanone, and the like. When cycloalkyl is a linking group, and "cycloalkyl" is recited for this markush group definition, then "cycloalkyl" means a linked cycloalkylene group. The term "cycloalkylene" refers to a divalent cycloalkane group formed by removal of two hydrogen atoms from a ring carbon atom of a cycloalkyl group. The cycloalkyl group or cycloalkane may independently be optionally substituted with one or more substituents described herein. The term "cycloalkylene" refers to a divalent saturated monocyclic carbon system formed by the removal of two hydrogen atoms from carbon atoms in a saturated carbocyclic ring. In some embodiments, cycloalkylene represents C 3-12 cycloalkylene, and in other embodiments, cycloalkylene represents C 3-10 cycloalkylene. In other embodiments, cycloalkylene means C 3-6 cycloalkylene. Examples of cycloalkylene include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and the like.
The term "hydroxyalkyl" denotes an alkyl group substituted with one or more hydroxy groups. In some embodiments, hydroxyalkyl represents alkyl substituted with 1,2,3, or 4 hydroxy groups. In some embodiments, hydroxyalkyl represents alkyl substituted with one or two hydroxyl groups. In some embodiments, hydroxyalkyl represents C 1-6 hydroxyalkyl, i.e., C 1-6 alkyl is substituted with one or more hydroxyl groups, preferably C 1-6 hydroxyalkyl represents, i.e., C 1-6 alkyl is substituted with one hydroxyl group. In some embodiments, hydroxyalkyl represents C 1-4 hydroxyalkyl. In some embodiments, hydroxyalkyl represents C 1-3 hydroxyalkyl. Examples of hydroxyalkyl groups include, but are not limited to ,CH2(OH)-、CH2(OH)CH2CH2CH2-、CH2(OH)CH2-、CH2(OH)CH2CH(OH)CH2-、CH(CH3)(OH)CH2CH(OH)CH2-, and the like.
The term "alkoxy" means that the alkyl group is attached to the remainder of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy groups contain 1 to 12 carbon atoms. In one embodiment, the alkoxy group contains 1 to 6 carbon atoms, in another embodiment, the alkoxy group contains 1 to 4 carbon atoms, and in yet another embodiment, the alkoxy group contains 1 to 3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents described herein. Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH 3), ethoxy (EtO, -OCH 2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH 2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH (CH 3)2), 1-butoxy (n-BuO, n-butoxy, -OCH 2CH2CH2CH3), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH 2CH(CH3)2), 2-butoxy (s-BuO), s-butoxy, -OCH (CH 3)CH2CH3), 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC (CH 3)3), 1-pentoxy (n-pentoxy), -OCH 2CH2CH2CH2CH3), 2-pentyloxy (-OCH (CH 3)CH2CH2CH3), 3-pentyloxy (-OCH (CH 2CH3)2), 2-methyl-2-butoxy (-OC (CH 3)2CH2CH3), 3-methyl-2-butoxy (-OCH (CH 3)CH(CH3)2), 3-methyl-l-butoxy (-OCH 2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH 2CH(CH3)CH2CH3), and the like.
The term "alkoxyalkyl" refers to an alkyl group substituted with one alkoxy group, wherein the alkoxy and alkyl groups have the definitions as described herein. In some embodiments, alkoxyalkyl represents C 1-6 alkoxyaC 1-6 alkyl, in other embodiments alkoxyalkyl represents C 1-4 alkoxyaC 1-4 alkyl, in other embodiments alkoxyalkyl represents C 1-4 alkoxyaC 1-3 alkyl, in some embodiments alkoxyalkyl represents C 1-3 alkoxyaC 1-3 alkyl. Examples of alkoxy groups include, but are not limited to, methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, methoxyethyl, methoxy-n-propyl, methoxyisopropyl, ethoxyethyl, ethoxy-n-propyl, ethoxyisopropyl, n-propoxyethyl, isopropoxyethyl, n-propoxyn-propyl, n-propoxyisopropyl, isopropoxy-n-propyl, isopropoxyiisopropyl, and the like.
The term "alkoxyalkoxy" refers to an alkoxy group substituted with one alkoxy group, wherein the alkoxy group has the definition as described herein. In some embodiments, alkoxyalkoxy represents C 1-6 alkoxy C 1-6 alkoxy, in other embodiments alkoxyalkyl represents C 1-4 alkoxy C 1-4 alkoxy, in other embodiments alkoxyalkyl represents C 1-4 alkoxy C 1-3 alkoxy, in some embodiments alkoxyalkyl represents C 1-3 alkoxy C 1-3 alkoxy. Examples of alkoxyalkoxy groups include, but are not limited to, methoxymethoxy, ethoxymethoxy, n-propoxymethoxy, isopropoxymethoxy, methoxyethoxy, methoxy-n-propoxy, methoxyisopropoxy, ethoxyethoxy, ethoxy-n-propoxy, ethoxyisopropoxy, n-propoxyethoxy, isopropoxy-ethoxy, n-propoxy, n-propoxy-isopropoxy, isopropoxy-n-propoxy, and the like.
The term "halogen" means F (fluorine), cl (chlorine), br (bromine) or I (iodine).
The term "oxo" means =o.
The term "haloalkyl" means an alkyl group substituted with one or more halogen atoms, examples of which include, but are not limited to, monofluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 1, 2-difluoroethyl, 1-difluoroethyl, 2-difluoroethyl, monochloromethyl dichloromethyl, trichloromethyl, 2-chloroethyl, 1, 2-dichloroethyl, 1-dichloroethyl, 2-dichloroethyl, 1-dibromoethyl, etc.
The term "haloalkoxy" means that the alkoxy group is substituted with one or more halogen atoms, examples of which include, but are not limited to, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 1, 2-difluoroethoxy, 1-difluoroethoxy, 2-difluoroethoxy, monochloromethoxy, dichloromethoxy, trichloromethoxy, 2-chloroethoxy, 1, 2-dichloroethoxy, 1-dichloroethoxy, 2-dichloroethoxy, 1-dibromoethoxy, and the like.
The term "alkanoyl" means an alkyl group attached to the remainder of the molecule through a carbonyl group, wherein alkyl has the definition as described herein, and carbonyl represents-C (=o) -. In some embodiments, the alkanoyl represents a C 1-6 alkanoyl, and in other embodiments, the alkanoyl represents a C 1-4 alkanoyl. Examples of alkanoyl groups include, but are not limited to, formyl, acetyl, and the like.
The term "aromatic ring" or "arene" means a monocyclic, bicyclic, and tricyclic carbocyclic ring system containing 6 to 14 ring atoms, or 6 to 12 ring atoms, or 6 to 10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system contains 3 to 7 atoms of a ring. Examples of the aromatic ring may include benzene, naphthalene and anthracene.
The term "aryl" refers to a monovalent aromatic ring radical formed by the removal of a hydrogen atom from a ring carbon atom of an aromatic ring. Examples of aryl groups may include phenyl, naphthyl and anthracenyl. When aryl is a linking group, then aryl represents a linked arylene group. M is a linked arylene group as defined herein. The term "arylene" refers to a divalent aromatic ring radical formed by the removal of two hydrogen atoms from a ring carbon atom of an aromatic ring. Examples of aryl groups represented as linked arylene groups may include phenylene, naphthylene, and anthracenylene. The aryl or arylene groups may independently be optionally substituted with one or more substituents described herein.
The term "heteroaryl ring" means monocyclic, bicyclic, and tricyclic ring systems containing 5 to 12 ring atoms, or 5 to 10 ring atoms, or 5 to 6 ring atoms, wherein at least one ring system is aromatic and at least one ring system contains one or more heteroatoms, wherein each ring system contains rings of 5 to 7 atoms.
The term "heteroaryl" refers to a monovalent aromatic ring radical formed by the removal of a hydrogen atom from a ring atom of a heteroaromatic ring. The heteroaryl group is optionally substituted with one or more substituents described herein. In one embodiment, the 5-10 atom composition heteroaryl or 5-10 membered heteroaryl contains 1,2,3 or 4 heteroatoms independently selected from O, S and N. In some embodiments, the term "heteroaryl" means a heteroaryl ring group containing 5-6 ring atoms or a 5-6 membered heteroaryl group containing 1,2,3, or 4 heteroatoms independently selected from O, S, and N. In some embodiments, the term "heteroaryl" denotes a heteroaryl ring group or a 5 membered heteroaryl group containing 5 ring atoms, which contains 1,2,3 or 4 heteroatoms independently selected from O, S and N. Examples of heteroaryl groups include, but are not limited to, 2-furyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2, 3-oxadiazolyl, 1,2, 5-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,2, 3-triazolyl, 1, 3-dithiotriazinyl, 1, 3-dithio, 3-triazolyl, 1, 3-triazolyl; also included are bicyclic rings of, but in no way limited to, benzimidazolyl, benzofuranyl, benzothienyl, indolyl (e.g., 2-indolyl), purinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl), and, imidazo [1,2-a ] pyridinyl, pyrazolo [1,5-a ] pyrimidinyl, imidazo [1,2-b ] pyridazinyl, [1,2,4] triazolo [4,3-b ] pyridazinyl, [1,2,4] triazolo [1,5-a ] pyrimidinyl, [1,2,4] triazolo [1,5-a ] pyridinyl, and the like. When heteroaryl is a linking group, then heteroaryl represents a linked heteroarylene group. M is a linked heteroarylene group as defined herein. The term "heteroarylene" refers to a divalent heteroaryl ring radical formed by removing two hydrogen atoms from a ring atom of a heteroaryl group. The heteroaryl or heteroarylene may be independently optionally substituted with one or more substituents described herein.
The term "aryloxy" means aryl-O-, i.e., an aryl group attached to the remainder of the molecule through an oxygen atom, wherein the aryl group has the definition as described herein. Examples of aryloxy groups include, but are not limited to, phenoxy, naphthoxy, and the like.
The term "aryloxyalkyl" denotes an aryloxy substituted alkyl group, wherein the aryloxy and alkyl groups have the definitions as described herein. In some embodiments, the aryloxyalkyl represents a C 6-10 aryloxyaC 1-6 alkyl group, in other embodiments, the aryloxyalkyl represents a phenoxy C 1-6 alkyl group, and in other embodiments, the aryloxyalkyl represents a phenoxy C 1-4 alkyl group. Specific examples of the aryloxyalkyl group include, but are not limited to, phenoxymethyl, phenoxyethyl, phenoxyn-propyl, phenoxyisopropyl, phenoxyn-butyl, phenoxyisobutyl, phenoxyt-butyl, and the like.
The term "Shan Tanhuan group" denotes a monovalent saturated or partially unsaturated, non-aromatic, monocyclic carbocyclic ring system in which the ring atoms are carbon atoms. In some embodiments, shan Tanhuan is a 3-7 membered Shan Tanhuan group, and in other embodiments, shan Tanhuan is a 3-6 membered monocyclocyclyl. Examples of Shan Tanhuan groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentadienyl, cyclohexenyl, and the like. When Shan Tanhuan groups are linking groups, the monocyclic groups represent linked sub Shan Tanhuan groups. The term "Shan Tanhuan-ene" means a divalent bridged carbocyclic radical formed by removing two hydrogen atoms from the ring atoms of a monocycle. The Shan Tanhuan or Shan Tanhuan groups may independently be optionally substituted with one or more substituents described herein.
The terms "bridged carbocycle" and "bridged carbocyclyl" are used interchangeably and each denote a non-aromatic, saturated or partially unsaturated, bicyclic or polycyclic ring system sharing two or more carbon atoms, with the ring atoms being carbon atoms. the-CH 2 -group in the bridged carbocycle can optionally be replaced by-C (=O) -. In some embodiments, the bridged carbocycle contains from 6 to 12 ring carbon atoms, meaning a 6-12 membered bridged carbocycle, and in other embodiments, the bridged carbocycle contains from 6 to 10 ring carbon atoms, meaning a 6-10 membered bridged carbocycle. Examples of bridged carbocycles include, but are not limited to, bicyclo [3.1.1] heptane, bicyclo [3.2.1] octane, bicyclo [2.2.2] octane, bicyclo [2.2.0] hexane, octahydro-1H-indene, and the like. When a bridged carbocycle or bridged carbocyclyl is a linking group, the bridged carbocycle or bridged carbocyclyl represents a linked, bridged carbocyclyl. The term "bridged carbocyclyl" means a divalent bridged carbocyclyl group formed by removing two hydrogen atoms from a ring atom of a bridged carbocycle. The bridged carbocycle or bridged carbocyclyl may independently be optionally substituted with one or more substituents described herein.
The terms "spirocarbocyclyl" and "spirocarbocyclyl" are used interchangeably and refer to a non-aromatic, saturated or partially unsaturated ring system formed by two carbocycles sharing one carbon atom. the-CH 2 -group in the spirocarbocyclic ring may optionally be replaced by-C (=o) -. In some embodiments, the spirocarbocycle contains 7-12 ring carbon atoms, meaning a 7-12 membered spirocarbocycle, and in other embodiments, the spirocarbocycle contains 7-10 ring carbon atoms, meaning a 7-10 membered spirocarbocycle. Examples of spiro carbocycles include, but are not limited to, spiro [4.4] nonane, spiro [3.4] octane, spiro [4.5] decane, and the like. When a spiro carbocycle or spiro carbocyclyl is a linking group, the spiro carbocycle or spiro carbocyclyl represents a linked spirocarbocyclylene group. The term "spiroylene" refers to a divalent spirocarbocyclic radical formed by removing two hydrogen atoms from the ring atoms of a spirocarbocyclic ring. The spirocarbocycle or spirocarbocyclyl may independently be optionally substituted with one or more substituents described herein.
The term "carbocyclyl" refers to a monovalent saturated or unsaturated, non-aromatic carbocyclic ring system in which the ring atoms are carbon atoms, including Shan Tanhuan groups, bridged carbocyclyl groups, and spiro carbocyclyl groups, wherein Shan Tanhuan groups, bridged carbocyclyl groups, and spiro carbocyclyl groups have the definitions as described herein. In some embodiments, carbocyclyl represents a 3-12 membered carbocyclyl, in other embodiments carbocyclyl represents a 3-10 membered carbocyclyl, in other embodiments carbocyclyl represents a 3-7 membered carbocyclyl, in other embodiments carbocyclyl represents a 3-6 membered carbocyclyl. The carbocyclyl groups may independently be optionally substituted with one or more substituents described herein. When carbocyclyl is a linking group, the term "carbocyclyl" is then denoted as "carbocyclylene".
The term "carbocyclylene" refers to a divalent carbocyclic system resulting from the removal of two hydrogen atoms from a carbocyclic hydrocarbon, including Shan Tanhuan, bridged and spiro-subgroup, wherein the subgroup Shan Tanhuan, bridged and spiro-subgroup have the definitions as described herein. In some embodiments, the carbon-containing ring group represents a 3-12 membered carbon-containing ring group, in other embodiments, the carbon-containing ring group represents a 3-10 membered carbon-containing ring group, in other embodiments, the carbon-containing ring group represents a 3-7 membered carbon-containing ring group. The carbon-containing ring groups may independently be optionally substituted with one or more substituents described herein.
The terms "mono-heterocyclic" or "mono-heterocyclyl" are used interchangeably and refer to a monovalent, non-aromatic, saturated or partially unsaturated monocyclic system containing at least 1 carbon atom and 1,2 or 3 heteroatoms selected from O, N, S. Unless otherwise specified, a heterocyclyl group may be a carbon or nitrogen group, and the-CH 2 -group may optionally be replaced by-C (=o) - (or- (c=o) -). The sulfur atom of the ring may optionally be oxidized to an S-oxide and the nitrogen atom of the ring may optionally be oxidized to an N-oxide. In some embodiments, the heterocycle contains 3-7 ring atoms, i.e., represents a 3-7 membered heterocycle, in some embodiments, the mono-heterocycle contains 4-7 ring atoms, i.e., represents a 4-7 membered heterocycle, and in other embodiments, the heterocycle contains 4-6 ring atoms, i.e., represents a 4-6 membered heterocycle. Examples of mono-heterocycles include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, 1, 3-dioxacyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thiazanyl, homopiperazinyl, homopiperidinyl, 1-dioxo-1, 3-thiomorpholin, and the like. Examples of the substitution of the-CH 2 -group in the heterocyclyl group by-C (=o) -include, but are not limited to, 2-oxo-pyrrolidinyl, oxo-1, 3-thiazolidinyl, 2-piperidonyl, 3, 5-dioxopiperidyl. Examples of the nitrogen atom in the heterocyclic group being oxidized to an N-oxy compound include, but are not limited to, 1-dioxo-1, 3-thiomorpholine. When a mono-heterocycle or mono-heterocyclyl is a linking group, the heterocycle or heterocyclyl represents a linked heterocyclylene group. The term "subunit" means a divalent heterocyclic group formed by removing two hydrogen atoms from a ring atom of a single heterocyclic ring. The mono-heterocycle or mono-heterocyclyl may independently be optionally substituted with one or more substituents described herein.
The terms "bridged heterocyclic ring" or "bridged heterocyclic group" are used interchangeably and refer to a non-aromatic, saturated or partially unsaturated, bicyclic or polycyclic ring system having a common use of two or more carbon atoms, and having at least 1 carbon atom, including 1,2, or 3 heteroatoms selected from O, N, S. the-CH 2 -group in the bridged heterocyclic ring can optionally be replaced by-C (=o) - (or- (c=o) -). The sulfur atom of the ring may optionally be oxidized to an S-oxide and the nitrogen atom of the ring may optionally be oxidized to an N-oxide. In some embodiments, the bridged heterocyclic ring contains 6-12 ring atoms, meaning a 6-12 membered bridged heterocyclic ring, and in other embodiments, the bridged heterocyclic ring contains 6-10 ring atoms, meaning a 6-10 membered bridged heterocyclic ring. Examples of bridged heterocycles include, but are not limited to, 3, 6-diazabicyclo [3.1.1] heptane, 3, 8-diazabicyclo [3.2.1] octane, 2-azabicyclo [2.2.1] heptane, octahydroimidazo [1,5-c ] pyrimidine, 6-azabicyclo [3.1.1] heptane, 3-azabicyclo [3.1.1] heptane, 8-azabicyclo [3.2.1] octane, 3-azabicyclo [3.2.1] octane, 2-diazabicyclo [2.2.2] octane, and the like. When bridged heterocycle or bridged heterocyclyl is a linking group, bridged heterocycle or bridged heterocyclyl represents a linked bridged heterocyclyl. The term "bridged heterocyclyl" means a divalent bridged heterocyclic group formed by removing two hydrogen atoms from a ring atom of a bridged heterocyclic ring. The bridged heterocycle or the bridged heterocyclyl may independently be optionally substituted with one or more substituents described herein.
The terms "spiroheterocycle" or "spiroheterocyclyl" are used interchangeably and refer to a non-aromatic, saturated or partially unsaturated ring system formed by two rings sharing one carbon atom, and which contains 1,2 or 3 heteroatoms selected from O, N, S. the-CH 2 -group in the spiroheterocycle may optionally be replaced by-C (=o) -. The sulfur atom of the ring may optionally be oxidized to an S-oxide and the nitrogen atom of the ring may optionally be oxidized to an N-oxide. In some embodiments, the spiroheterocycle contains 7-12 ring atoms, meaning a 7-12 membered spiroheterocycle, and in other embodiments, the spiroheterocycle contains 7-10 ring atoms, meaning a 7-10 membered spiroheterocycle. Examples of spiroheterocycles include, but are not limited to, 4, 7-diazaspiro [2.5] octane, 2, 8-diazaspiro [4.5] decane, 2, 7-diazaspiro [3.5] decane, 2, 6-diazaspiro [3.3] heptane, 2, 7-diazaspiro [4.4] nonane, 3-azaspiro [5.5] undecane, 2, 7-diazaspiro [4.4] nonane-1-one, and the like. When a spiroheterocycle or spiroheterocyclyl is a linking group, the spiroheterocycle or spiroheterocyclyl represents a linked spiroheterocyclyl. The term "spiroylene" means a divalent spiroheterocyclic group formed by removing two hydrogen atoms from a ring atom of a spiroheterocyclic ring. The spiroheterocycle or spiroheterocyclyl may independently be optionally substituted with one or more substituents described herein.
The term "heterocyclyl" means a monovalent, non-aromatic, saturated or partially unsaturated heterocyclic ring system containing at least 1 carbon atom and 1,2 or 3 heteroatoms selected from O, N, S. The heterocyclic group may be a monocyclic or bicyclic ring system, and in particular, the bicyclic ring system may be a heterobicyclic ring, a spiroheterobicyclic ring or a bridged heterobicyclic ring. Specific heterocyclyl groups include mono-, bridged-and or spiro-heterocyclyl groups, wherein mono-, bridged-and spiro-heterocyclyl groups have the definitions as described herein. In some embodiments, heterocyclyl represents a 3-12 membered heterocyclyl, in other embodiments, heterocyclyl represents a 3-10 membered heterocyclyl, in other embodiments, heterocyclyl represents a 3-7 membered heterocyclyl, in other embodiments, heterocyclyl represents a 3-6 membered heterocyclyl.
When heterocyclyl is a linking group, the term "heterocyclyl" is then intended to mean "heterocyclylene". That is, the term "heterocyclylene" means a divalent heterocyclic ring system formed by removing two hydrogen atoms from carbon atoms in a heterocyclic ring, wherein the system contains at least 1 carbon atom, 1,2 or 3 heteroatoms selected from O, N, S. The heterocyclylene group includes a monoylene group, a bridged heterocyclic group and a spiro heterocyclic group, wherein the monoylene group, the bridged heterocyclic group and the spiro heterocyclic group have the definitions as described in the present invention. In some embodiments, a heterocyclylene group represents a divalent heterocyclic ring system formed by the removal of two hydrogen atoms from the same carbon atom in a heterocyclic ring. In some embodiments, the heterocyclylene represents a 3-7 membered heterocyclylene, and in other embodiments, the heterocyclylene represents a 3-6 membered heterocyclylene. Examples of heterocyclylene include, but are not limited to, ethylene oxide, aziridine, oxetane, oxolane, azetidine, and the like.
The term "alkylaryl" refers to an aryl group substituted with an alkyl group, wherein the alkyl and aryl groups have the definitions as set forth herein. In some embodiments, "alkylaryl" means C 1-6 alkyl-C 6-10 aryl, i.e., C 6-10 aryl substituted with C 1-6 alkyl, and in other embodiments, "alkylaryl" means C 1-4 alkylphenyl, i.e., phenyl substituted with C 1-4 alkyl. Examples of alkylaryl groups include, but are not limited to, methylphenyl, ethylphenyl, propylphenyl, methylnaphthyl, and the like. When alkylaryl is a linking group, alkylaryl represents a linked alkylene aryl. M is a linked alkylene aryl group as defined herein. The term "alkylene arylene" refers to a divalent alkylene arylene group formed by the removal of one hydrogen atom from an alkyl group of an alkylaryl ring and the removal of one hydrogen atom from a ring atom of an aryl ring. The alkylaryl or alkylene arylene groups may independently be optionally substituted with one or more substituents described herein.
The term "arylalkyl" denotes an alkyl group substituted with an aryl group, wherein the alkyl and aryl groups have the definitions as described herein. In some embodiments, "arylalkyl" means C 6-10 arylC 1-6 alkyl, i.e., C 1-6 alkyl substituted with C 6-10 aryl, in other embodiments, "arylalkyl" means phenylC 1-6 alkyl, i.e., C 1-6 alkyl substituted with phenyl, and in other embodiments, "arylalkyl" means phenylC 1-4 alkyl, i.e., C 1-4 alkyl substituted with phenyl. Examples of arylalkyl groups include, but are not limited to, phenylmethyl, phenylethyl, phenylpropyl, phenyl-n-butyl, phenylisobutyl, phenylt-butyl, naphthylmethyl, and the like. When arylalkyl is a linking group, arylalkyl represents the linked arylene alkylene. M is a linked arylene alkylene group as defined herein. The term "arylene alkylene" refers to a divalent alkylene arylene group formed by the removal of one hydrogen atom from an aryl group of an arylalkane and the removal of one hydrogen atom from a ring atom of an alkane. The arylalkyl group or the arylalkylene group may independently be optionally substituted with one or more substituents described herein.
The term "alkylheteroaryl" refers to heteroaryl substituted with an alkyl group. Wherein alkyl and heteroaryl have the definitions as described herein. In some embodiments, "alkylheteroaryl" means C 1-6 alkyl- (5-10 membered heteroaryl), i.e., a 5-10 membered heteroaryl substituted with C 1-6 alkyl, and in other embodiments, "alkylheteroaryl" means C 1-4 alkyl- (5-6 membered heteroaryl), i.e., a 5-6 membered heteroaryl substituted with C 1-4 alkyl. Examples of alkylheteroaryl groups include, but are not limited to, methylpyridinyl, ethylpyridyl, propylpyridinyl, methylpyrazolyl, ethylpyrazolyl, propylpyrazolyl, methylpyrimidinyl, methylpyrazinyl, methylbenzimidazolyl, methylbenzopyrazinyl, and the like. When alkyl heteroaryl is a linking group, then alkyl heteroaryl represents a linked alkylene heteroarylene. The term "alkylene heteroarylene" refers to a divalent alkylene heteroarylene group formed by removing one hydrogen atom from an alkyl group of an alkyl heteroaryl ring and one hydrogen atom from a ring atom of a heteroaryl ring. The alkylheteroaryl group or alkylideneheteroaryl group may be independently optionally substituted with one or more substituents described herein.
The term "heteroarylalkyl" refers to an alkyl group substituted with a heteroaryl group. Wherein alkyl and heteroaryl have the definitions as described herein. In some embodiments, "heteroarylalkyl" means (5-10 membered heteroaryl) -C 1-6 alkyl, i.e., C 1-6 alkyl substituted with 5-10 membered heteroaryl, in other embodiments, "heteroarylalkyl" means (5-10 membered heteroaryl) -C 1-4 alkyl, i.e., C 1-4 alkyl substituted with 5-10 membered heteroaryl, and in other embodiments, "heteroarylalkyl" means (5-6 membered heteroaryl) -C 1-4 alkyl, i.e., C 1-4 alkyl substituted with 5-6 membered heteroaryl. Examples of heteroarylalkyl groups include, but are not limited to, imidazolylmethyl, imidazolylethyl, pyridylmethyl, pyridylethyl, pyridylpropyl, pyrazolylmethyl, pyrazolylethyl, pyrazolylpropyl, imidazolylmethyl, imidazolylethyl, pyrimidinylmethyl, pyrazinylmethyl, imidazolylmethyl, imidazolylethyl, benzimidazolylmethyl, benzopyrazolylmethyl, pyrazolo [1,5-a ] pyrimidinylmethyl, and the like. When heteroarylalkyl is a linking group, then heteroarylalkyl represents a linked heteroarylalkylene group. The term "alkylidene heteroarylalkylene" refers to a divalent alkylidene heteroarylalkylene group formed by the removal of one hydrogen atom from the heteroaryl of a heteroarylalkane and the removal of one hydrogen atom from the alkane. The heteroarylalkyl group or alkylidene heteroarylalkylene may be independently optionally substituted with one or more substituents described herein.
The term "alkylene heterocyclylalkylene" means that the heterocyclyl on the heterocyclylalkyl group is substituted with an alkylene group. In some embodiments, alkylene heterocycloalkylene denotes C 1-6 alkylene- (3-12 membered heterocycloalkylene) -C 1-6 alkylene, in other embodiments alkylene heterocycloalkylene denotes C 1-6 alkylene- (3-6 membered heterocycloalkylene) -C 1-6 alkylene, and in other embodiments alkylene heterocycloalkylene denotes C 1-4 alkylene- (3-6 membered heterocycloalkylene) -C 1-4 alkylene. Examples of alkylene heterocycloalkylene include, but are not limited to, -CH 2 -piperazinylene-CH 2-、-CH2 -piperidinyl-CH 2 -, and the like. The alkylene heterocyclylene alkylene groups may independently be optionally substituted with one or more substituents described herein.
The term "alkylene heteroarylalkylene" means that the heteroaryl group on the heteroarylalkyl group is substituted with an alkylene group. In some embodiments, the alkylidene heteroarylalkylene represents C 1-6 alkylene- (5-10 membered heteroaryl) -C 1-6 alkylene, in other embodiments, the alkylidene heteroarylalkylene represents C 1-4 alkylene- (5-10 membered heteroaryl) -C 1-4 alkylene, and in other embodiments, the alkylidene heteroarylalkylene represents C 1-4 alkylene- (5-6 membered heteroaryl) -C 1-4 alkylene. Examples of alkylene heteroarylalkylene groups include, but are not limited to, -CH 2 -oxazolylene-CH 2-、-CH2 -imidazolylene-CH 2 -, and the like. The alkylene heteroarylene groups may be independently optionally substituted with one or more substituents described herein.
The term "aminoalkyl" refers to an alkyl group substituted with one or more amino groups. In some embodiments, the term "aminoalkyl" refers to an alkyl group substituted with one amino group. In some embodiments, the term "aminoalkyl" means a C 1-6 aminoalkyl group. In other embodiments, the term "aminoalkyl" means a C 1-4 aminoalkyl group. In other embodiments, the term "aminoalkyl" means a C 1-3 aminoalkyl group. Examples of aminoalkyl groups include, but are not limited to, aminomethyl, aminoethyl, amino-n-propyl, amino-isopropyl, amino-isobutyl, amino-t-butyl, 1, 2-diaminoethyl, and the like.
The term "alkylamino" refers to an amino group substituted with one alkyl group. In some embodiments, the term "alkylamino" means a C 1-6 alkylamino. In other embodiments, the term "alkylamino" means a C 1-4 alkylamino. In other embodiments, the term "alkylamino" means a C 1-3 alkylamino. Examples of alkylamino groups include, but are not limited to, methylamino, ethylamino, n-propylamino, isopropylamino, isobutylamino, tert-butylamino, and the like.
The term "alkylsulfonyl" denotes an alkyl-S (=o) 2 -, i.e. an alkyl group is attached to the remainder of the molecule through-S (=o) 2 -. In some embodiments, alkylsulfonyl represents C 1-6 alkylsulfonyl, in other embodiments alkylsulfonyl represents C 1-4 alkylsulfonyl, in other embodiments alkylsulfonyl represents C 1-4 alkylsulfonyl. Examples of alkylsulfonyl groups include, but are not limited to, methylsulfonyl, ethylmethylsulfonyl, n-propylmethylsulfonyl, isopropylmethylsulfonyl, n-butylmethylsulfonyl, and the like.
The term "carbocyclylalkyl" means that a hydrogen atom on an alkyl group is replaced with a carbocyclyl group. Wherein alkyl and carbocyclyl have the definitions as described herein. In some embodiments, carbocyclylalkyl represents (3-12 membered carbocyclyl) -C 1-6 alkyl, in some embodiments carbocyclylalkyl represents (3-10 membered carbocyclyl) -C 1-6 alkyl, in other embodiments carbocyclylalkyl represents (3-10 membered carbocyclyl) -C 1-4 alkyl, and in other embodiments carbocyclylalkyl represents (3-6 membered carbocyclyl) -C 1-4 alkyl. Examples of carbocyclylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl, cyclopropylethyl, cyclobutylethyl, cyclobutylpropyl, cyclohexylethyl, cyclohexylmethyl, and the like. When carbocyclylalkyl is represented as a linking group, then carbocyclylalkyl represents a linked carbocyclylalkylene. The term "carbocyclylene" refers to a divalent carbocyclylene alkylene group formed by removing one hydrogen atom from the carbocyclyl of a carbocyclylalkane and one hydrogen atom from the alkane. The carbocyclylalkyl and carbocyclylene alkylene groups may be independently optionally substituted with one or more substituents described herein.
The term "alkyl carbocyclyl" means that a hydrogen atom on the carbocyclyl is substituted with an alkyl group, wherein alkyl and carbocyclyl have the definitions as described herein. In some embodiments, an alkyl carbocyclyl represents a C 1-6 alkyl- (3-12 membered carbocyclyl), in some embodiments, an alkyl carbocyclyl represents a C 1-6 alkyl- (3-10 membered carbocyclyl), in some embodiments, an alkyl carbocyclyl represents a C 1-6 alkyl- (3-6 membered carbocyclyl), in some embodiments, an alkyl carbocyclyl represents a C 1-4 alkyl- (3-6 membered carbocyclyl), examples of alkyl carbocyclyl include, but are not limited to, methylcyclopropyl, ethylcyclopropyl, methylcyclobutyl, methylcyclopentyl, ethylcyclohexyl, methylcyclohexyl, and the like. When an alkyl carbocyclyl is denoted as a linking group, then the alkyl carbocyclyl denotes a linked alkylene carbocyclylene. The term "alkylene carbocyclylene" refers to a divalent alkylene carbocyclylene group formed by removing one hydrogen atom from an alkyl group of an alkyl carbocycle and one hydrogen atom from a carbocycle. The alkyl carbocyclyl and alkylene carbocyclyl groups may be independently optionally substituted with one or more substituents described herein.
The term "heterocyclylalkyl" denotes an alkyl group substituted with a heterocyclyl group, wherein the alkyl and heterocyclyl groups have the definitions as described herein. In some embodiments, "heterocyclylalkyl" means (3-12 membered heterocyclyl) -C 1-6 alkyl, in other embodiments heterocyclylalkyl means (3-10 membered heterocyclyl) -C 1-6 alkyl, in other embodiments heterocyclylalkyl means (3-7 membered heterocyclyl) -C 1-6 alkyl, in other embodiments heterocyclylalkyl means (3-6 membered heterocyclyl) -C 1-4 alkyl. Examples of heterocyclylalkyl groups include, but are not limited to, azetidinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, morpholinylethyl, piperazinylmethyl, piperazinylethyl, 2-oxopyrrolidinylmethyl, 2-oxopyrrolidinylethyl, oxetanylmethyl, tetrahydrofuranylmethyl, and the like. When heterocyclylalkyl is a linking group, the term "heterocyclylalkyl" means "heterocyclylalkylene". The term "heterocycloalkylene" refers to a divalent heterocycloalkylene group formed by the removal of one hydrogen atom from the heterocyclic group of a heterocycloalkane and the removal of one hydrogen atom from the alkane. . The heterocyclylalkyl or heterocyclylalkylene groups may be independently optionally substituted with one or more substituents described herein.
The term "alkylheterocyclyl" denotes heterocyclyl substituted with an alkyl group, wherein the alkylheterocyclyl has the definition as described herein. In some embodiments, "alkylheterocyclyl" means C 1-6 alkyl- (3-12 membered heterocyclyl); "alkylheterocyclyl" means C 1-6 alkyl- (3-10 membered heterocyclyl); in other embodiments, "alkylheterocyclyl" means C 1-4 alkyl- (3-10 membered heterocyclyl); in other embodiments, "alkylheterocyclyl" means C 1-4 alkyl- (3-6 membered heterocyclyl). Examples of alkyl heterocyclyl groups include, but are not limited to, isopropyl azetidinyl, methylpiperidinyl, methyl oxetanyl, methylpyrrolidinyl, methylmorpholinyl, methylimidazolidinyl, and the like. When an alkylheterocyclyl is a linking group, the term "alkylheterocyclyl" means "alkylene heterocyclyl". The term "alkylene heterocyclylene" means a divalent alkylene heterocyclylene group formed by the removal of one hydrogen atom from the alkyl group of an alkyl heterocyclic hydrocarbon and the removal of one hydrogen atom from a heterocyclic hydrocarbon. The alkylheterocyclyl or alkylidenyl heterocyclyl group may independently be optionally substituted with one or more substituents described herein.
In the general formula of the compounds of the invention, the left end of Q is linked to the ring A and the right end of Q is linked to M, e.g. when Q is-S (=O) 2NR5 -, thenRepresentation of
In the general formula of the compounds of the invention, T is used as a linking group, and the two ends of the T are interchangeably linked toAnd on the group Y, for example, when T is a specific group-CH 2CH(CH3) -and,Representation ofOr (b)In both cases, when T is a specific group- (CH 2)2OCH2) -for example,Representation ofOr (b)Both cases.
As described herein, unless otherwise specified, a ring substituent may be attached to the remainder of the molecule through any available position on the ring. For example, piperidinyl includes piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, and piperidin-4-yl.
If two attachment points are attached to the remainder of the molecule on a ring, as described herein, the two attachment points may be attached to the remainder of the molecule at any attachable location on the ring, with the ends of the attachment being interchangeable. For example, the sub-formula a1 of ring a represents that any two possible locations on the ring that may be connected may be used as points of connection (i.e., attachment points), while the two ends of the connection points may be interchanged. Preferably, if there are two attachment points on a ring that are attached to the remainder of the molecule, the two attachment points may be attached to the remainder of the molecule at any attachable position on the ring, and the two attachment points are attached to two different ring atoms on the ring.
Preferably, in the present invention, if one ring is a parallel ring or a spiro ring formed of two sub-rings, and two attachment points on the ring are respectively located on the two sub-rings, the two attachment points are respectively connected with the rest of the molecule at any connectable positions on the two sub-rings, and both ends of the connection may be interchanged. For example, the sub-formula a2 of ring A preferably represents that two attachment points on the ring are attached to the remainder of the molecule on the H1 ring and the H2 ring, respectively, while the two ends of the attachment can be interchanged, and the sub-formula a3 of ring A preferably represents that two attachment points on the ring are attached to the remainder of the molecule on the H1 'ring and the H2' ring, respectively, while the two ends of the attachment can be interchanged.
Specifically, for example, when ring A isWhen used herein, means that two attachment points on the A ring are interchangeably attached to the E and Q groups in the general formula of the compounds of the invention, namely: Represented as
The term "protecting group" or "PG" refers to a substituent that is commonly used to block or protect a particular functionality when reacted with other functional groups. For example, by "protecting group for an amino group" is meant a substituent attached to the amino group to block or protect the functionality of the amino group in the compound, suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC ), benzyloxycarbonyl (CBZ ) and 9-fluorenylmethoxycarbonyl (Fmoc). Similarly, "hydroxy protecting group" refers to the functionality that a substituent of a hydroxy group serves to block or protect the hydroxy group, and suitable protecting groups include acetyl and silyl. "carboxy protecting group" refers to the functionality of a substituent of a carboxy group to block or protect the carboxy group, and typical carboxy protecting groups include-CH 2CH2SO2 Ph, cyanoethyl, 2- (trimethylsilyl) ethyl, 2- (trimethylsilyl) ethoxymethyl, 2- (p-toluenesulfonyl) ethyl, 2- (p-nitrobenzenesulfonyl) ethyl, 2- (diphenylphosphino) ethyl, nitroethyl, and the like. General description of protecting groups can be found in the literature ：T W.Greene,Protective Groups in Organic Synthesis,John Wiley&Sons,New York,1991;and P.J.Kocienski,Protecting Groups,Thieme,Stuttgart,2005.
The term "prodrug" as used herein means a compound that is converted in vivo to a compound of formula (I). Such conversion is effected by hydrolysis of the prodrug in the blood or enzymatic conversion to the parent structure in the blood or tissue. The prodrug of the invention can be esters, and in the prior invention, the esters can be phenyl esters, aliphatic (C 1-24) esters, acyloxymethyl esters, carbonic esters, carbamates and amino acid esters as the prodrugs. For example, one compound of the invention may contain a hydroxyl group, i.e., it may be acylated to provide the compound in a prodrug form. Other prodrug forms include phosphates, such as those obtained by phosphorylation of a hydroxyl group on the parent. For a complete discussion of prodrugs, reference may be made to the following documents ：T.Higuchi and V.Stella,Pro-drugs as Novel Delivery Systems,Vol.14of the A.C.S.Symposium Series,Edward B.Roche,ed.,Bioreversible Carriers in Drug Design,American Pharmaceutical Association and Pergamon Press,1987,J.Rautio et al.,Prodrugs:Design and Clinical Applications,Nature Review Drug Discovery,2008,7,255-270,and S.J.Hecker et al.,Prodrugs of Phosphates and Phosphonates,Journal of Medicinal Chemistry,2008,51,2328-2345.
"Metabolite" refers to a product obtained by metabolizing a specific compound or salt thereof in vivo. The metabolites of a compound may be identified by techniques well known in the art and their activity may be characterized by employing the assay methods as described herein. Such products may be obtained by oxidation, reduction, hydrolysis, amidization, deamination, esterification, degreasing, enzymatic cleavage, etc. of the administered compound. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a period of time sufficient.
As used herein, "pharmaceutically acceptable salts" refers to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in document ：S.M.Berge et al.,describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences,1977,66:1-19.. Pharmaceutically acceptable non-toxic acid forming salts include, but are not limited to, inorganic acid salts formed by reaction with amino groups such as hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and organic acid salts such as acetate, oxalate, maleate, tartrate, citrate, succinate, malonate, or by other methods described in the literature such as ion exchange. Other pharmaceutically acceptable salts include adipic acid salts, alginates, ascorbates, aspartic acid salts, benzenesulfonates, benzoic acid salts, bisulfate salts, borates, butyric acid salts, camphoric acid salts, cyclopentylpropionates, digluconate, dodecylsulfate, ethanesulfonate, formate salts, fumaric acid salts, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, caproate, hydroiodic acid salts, 2-hydroxy-ethanesulfonate salts, lactobionic aldehyde salts, lactate salts, laurate salts, lauryl sulfate, malate salts, malonate salts, methanesulfonate salts, 2-naphthalenesulfonate salts, nicotinate salts, nitrate salts, oleate salts, palmitate salts, pamoate salts, pectate salts, persulfate salts, 3-phenylpropionate salts, picrate salts, pivalate salts, propionate salts, stearate salts, thiocyanate salts, p-toluenesulfonate salts, undecanoate salts, valerate salts, and the like. Salts obtained with suitable bases include the alkali metal, alkaline earth metal, ammonium and N +(C1-4 alkyl) 4 salts. The present invention also contemplates quaternary ammonium salts formed from any compound containing a group of N. The water-soluble or oil-soluble or dispersible product may be obtained by quaternization. Alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include suitable, non-toxic ammonium, quaternary ammonium salts and counter-ion forming amine cations such as halides, hydroxides, carboxylates, sulphates, phosphates, nitrates, C 1-8 sulphonates and aromatic sulphonates.
Pharmaceutically acceptable salts of the invention can be synthesized from the parent compound, basic or acidic moiety using conventional chemical methods. In general, such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of a suitable base (e.g., na, ca, mg or K hydroxide, carbonate, bicarbonate, etc.), or by reacting the free base forms of these compounds with a stoichiometric amount of a suitable acid. Such reactions are generally carried out in water or an organic solvent or a mixture of both. Generally, it is desirable to use a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile where appropriate. A list of further suitable salts can be found in, for example, "Remington's Pharmaceutical Sciences", 20 th edition, mack Publishing Company, easton, pa., (1985), and "handbook of pharmaceutically acceptable salts: properties, choices and applications (Handbook of Pharmaceutical Salts：Properties,Selection,and Use)",Stahl and Wermuth(Wiley-VCH,Weinheim,Germany,2002).
In addition, the compounds disclosed herein, including their salts, may also be obtained in the form of their hydrates or in the form of solvents (e.g., ethanol, DMSO, etc.) containing them, for their crystallization. The disclosed compounds may form solvates inherently or by design with pharmaceutically acceptable solvents (including water) and, thus, the invention is intended to include both solvated and unsolvated forms.
"Solvate" according to the present invention refers to an association of one or more solvent molecules with a compound according to the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, acetic acid, and aminoethanol. The term "hydrate" refers to an association of solvent molecules that are water.
"Nitroxide" in the present invention means that when a compound contains several amine functions, 1 or more than 1 nitrogen atom can be oxidized to form an N-oxide. Specific examples of N-oxides are N-oxides of tertiary amines or N-oxides of nitrogen atoms of nitrogen-containing heterocycles. The corresponding amine may be treated with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid) to form an N-oxide (see Advanced Organic Chemistry, WILEY INTERSCIENCE, 4 th edition, jerry March, pages). In particular, the N-oxides can be prepared by the method L.W.Deady (Syn.Comm.1977, 7, 509-514) in which an amine compound is reacted with m-chloroperoxybenzoic acid (MCPBA), for example in an inert solvent such as methylene chloride.
The term "treating" as used herein refers in some embodiments to ameliorating a disease or disorder (i.e., slowing or preventing or alleviating the progression of the disease or at least one clinical symptom thereof). In other embodiments, "treating" refers to moderating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" refers to modulating a disease or disorder physically (e.g., stabilizing a perceived symptom) or physiologically (e.g., stabilizing a parameter of the body) or both. In other embodiments, "treating" refers to preventing or delaying the onset, or exacerbation of a disease or disorder.
The term "RET related cancer" as used herein refers to cancers associated with deregulation of the expression or activity or level of the RET gene, RET kinase (also referred to herein as RET kinase protein or RET kinase) or any of them. Non-limiting examples of RET-related cancers are described. The deregulation of the expression or activity or level of the RET gene, RET kinase or any one thereof is one or more point mutations in the RET gene. In some embodiments, the deregulation of the expression or activity or level of the RET gene, the RET kinase or any of them comprises one or more deletions (e.g., deletion of amino acid 4), insertions or point mutations in the RET kinase.
The term "irritable bowel syndrome" includes diarrhea predominant, constipation predominant or alternating stool patterns, functional bloating, functional constipation, functional diarrhea, nonspecific functional bowel disease, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disease, functional gastroduodenal disease, functional anorectal pain, inflammatory bowel disease, and the like.
Any formulae given herein are also intended to represent non-isotopically enriched forms as well as isotopically enriched forms of such compounds. Isotopically enriched compounds have structures depicted by the formulae given herein except that one or more atoms are replaced by an atom having a selected atomic or mass number. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2H,3H,11C,13C,14C,15N,17O,18O,18F,31P,32P,35S,36Cl and 125 I.
In another aspect, the compounds of the invention include isotopically enriched compounds defined herein, for example, those in which a radioisotope, such as 3H,14 C and 18 F, is present, or in which a non-radioisotope, such as 2 H and 13 C, is present. Such isotopically enriched compounds are useful in metabolic studies (using 14 C), kinetic studies (using, for example, 2 H or 3 H), detection or imaging techniques, such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) including drug or substrate tissue distribution assays, or in radiation therapy of patients. 18 F-enriched compounds are particularly desirable for PET or SPECT studies. Isotopically enriched compounds of formula (I), (I-1), (I-2) or (I-3) can be prepared by conventional techniques familiar to those skilled in the art or by describing the examples and processes of preparation in the present invention using a suitable isotopically labelled reagent in place of the originally used unlabelled reagent.
Furthermore, substitution of heavier isotopes, particularly deuterium (i.e., 2 H or D), may afford certain therapeutic advantages resulting from greater metabolic stability. For example, increased in vivo half-life or reduced dosage requirements or improved therapeutic index. It is to be understood that deuterium in the context of the present invention is considered a substituent for a compound of formula (I), (I-1), (I-2) or (I-3). The concentration of such heavier isotopes, particularly deuterium, can be defined by an isotopic enrichment factor. The term "isotopically enriched factor" as used herein refers to the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent of a compound of the invention is designated as deuterium, the compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent may be isotopically substituted, e.g. D 2 O, acetone-D 6、DMSO-d6.
Compounds of the present invention and pharmaceutical compositions, formulations and administration thereof
The present invention provides compounds of the invention or pharmaceutical compositions thereof that inhibit RET wild-type and RET mutants. In addition, the compounds of the present invention or pharmaceutical compositions thereof have inhibitory selectivity for both RET wild-type and RET gene mutants over other kinases, resulting in reduced toxicity associated with inhibition of other kinases.
The pharmaceutical composition of the present invention comprises a compound represented by formula (I), (I-1), (I-2) or (I-3), a compound listed in the present invention, or a compound of the examples. The amount of the compound in the pharmaceutical compositions of the invention is effective to treat or reduce RET-associated diseases or conditions in a patient, including RET-associated cancers, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
As described herein, the pharmaceutically acceptable compositions of the present invention further comprise pharmaceutically acceptable adjuvants, which as used herein, include any solvent, diluent, or other liquid excipient, dispersant or suspending agent, surfactant, isotonic agent, thickening agent, emulsifying agent, preservative, solid binder or lubricant, and the like, as appropriate for the particular target dosage form. ：In Remington:The Science and Practice of Pharmacy,21st edition,2005,ed.D.B.Troy,Lippincott Williams&Wilkins,Philadelphia,and Encyclopedia of Pharmaceutical Technology,eds.J.Swarbrick and J.C.Boylan,1988-1999,Marcel Dekker,New York,, as described in the following documents, taken together with the content of the documents herein, demonstrate that various adjuvants can be employed in the preparation of pharmaceutically acceptable compositions and their known methods of preparation. In addition to the extent to which any conventional adjuvant is incompatible with the compounds of the present invention, such as any adverse biological effects produced or interactions with any other component of the pharmaceutically acceptable composition in a deleterious manner, their use is also contemplated by the present invention.
In preparing the pharmaceutical compositions provided herein, the active ingredient is typically admixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, pouch, paper or other container. If an excipient is used as a diluent, it may be a solid, semi-solid, or liquid material, which acts as a carrier, vehicle, or medium for the active ingredient. Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Thus, the compositions may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders. In one embodiment, the composition is formulated for oral administration. In one embodiment, the composition is formulated as a tablet or capsule.
When useful in therapy, a therapeutically effective amount of a compound of the present invention, particularly a compound of formula (I), (I-1), (I-2) or (I-3), and pharmaceutically acceptable salts thereof, may be administered as a raw chemical, and may also be provided as an active ingredient in a pharmaceutical composition. Accordingly, the present disclosure also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the present invention, particularly a compound of formula (I), (I-1), (I-2) or (I-3), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable adjuvants, including, but not limited to, carriers, diluents or excipients, and the like. The term "therapeutically effective amount" as used herein refers to the total amount of each active ingredient sufficient to exhibit a meaningful patient benefit (e.g., cancer cytopenia). When separate active ingredients are used for separate administration, the term refers only to the ingredient. When applied in combination, the term refers to the combined amounts of the active ingredients that, when administered sequentially or simultaneously, result in a therapeutic effect. The compounds of the present invention, especially those of formula (I), (I-1), (I-2) or (I-3) and pharmaceutically acceptable salts thereof, as described above, must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. According to a further aspect of the present invention there is also provided a process for the preparation of a pharmaceutical formulation which comprises mixing a compound of the present invention, particularly a compound of formula (I), (I-1), (I-2) or (I-3), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients. The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for use in the intended use.
The amount of active ingredient combined with one or more adjuvants to prepare a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. The amount of the compound of formula (I), (I-1), (I-2) or (I-3) in admixture with a carrier material to prepare a single dosage form will vary depending upon the disease to be treated, the severity of the disease, the time of administration, the route of administration, the rate of excretion of the compound used, the time of treatment and the age, sex, weight and condition of the patient. Preferred unit dosage forms are those containing a daily dose or divided dose of the above-described active ingredient of the invention or a suitable fraction thereof. Treatment may be initiated with a small dose that is significantly less than the optimal dose of the compound. Thereafter, the dosage is increased in smaller increments until the optimal effect is reached in this case. In general, the most desirable levels of concentration at which the compound is administered are those that generally provide effective results in terms of anti-tumor efficacy without causing any deleterious or toxic side effects.
Compositions comprising the compounds of the invention may be formulated in unit dosage forms, each dosage comprising from about 5 to about 1,000mg (1 g), more typically from about 100mg to about 500mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects or other patients, each unit containing a predetermined quantity of active material, i.e. a compound of formula (I) as provided herein, calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The pharmaceutical composition is suitable for administration by any suitable route, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intradermal, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, intravenous or true subcutaneous injection or infusion) route. Such formulations may be prepared by any method known in the pharmaceutical arts, for example, by mixing the active ingredient with carriers or excipients. Oral administration or injection administration is preferred.
The invention also provides methods of treating an individual having RET-associated cancer comprising administering a compound of the invention before, during or after administration of another anti-cancer agent (e.g., not a compound of the invention).
The invention provides methods for treating cancer in a patient in need thereof, comprising (a) determining whether the cancer in the patient is a RET related cancer (e.g., a RET related cancer comprising a RET inhibitor resistance mutation (s)) using regulatory agency approved, e.g., FDA approved, kits to identify deregulation of the expression or activity or level of the RET gene, RET kinase, or any of them in the patient or in a biopsy sample of the patient, or by performing any non-limiting examples of the assays described herein, and (b) administering to the patient a therapeutically effective amount of a compound of formula (I), (I-1), (I-2), or (I-3), or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof, if the cancer is determined to be a RET related cancer. Some embodiments of these methods further comprise administering to the subject another anti-cancer agent (e.g., another RET inhibitor, e.g., a RET inhibitor that is not a compound of the invention). In some embodiments, the subject was previously treated with a RET inhibitor that is not a compound of formula (I), (I-1), (I-2), or (I-3), or a pharmaceutically acceptable salt or solvate thereof, or was previously treated (e.g., after excision of a tumor or radiation therapy) with another anticancer agent.
In some embodiments of any of the methods described herein, a compound of formula (I), (I-1), (I-2), or (I-3) (or a pharmaceutically acceptable salt or solvate thereof) is used in combination with a therapeutically effective amount of at least one additional therapeutic agent selected from one or more additional therapeutic or therapeutic (e.g., chemotherapeutic) agents.
Non-limiting examples of other therapeutic agents include other RET targeted therapeutic agents (i.e., other RET kinase inhibitors, RET inhibitors other than the compounds of the present invention), receptor tyrosine kinase targeted therapeutic agents, signal transduction pathway inhibitors, checkpoint inhibitors, apoptosis pathway modulators (e.g., obataclax), cytotoxic chemotherapeutic agents, angiogenesis targeted therapeutic agents, immune targeting agents, and radiation therapies.
In some embodiments, the other RET targeted therapeutic agent is a multi-kinase inhibitor that exhibits RET inhibitory activity.
Non-limiting examples of RET targeted therapeutic agents include alatinib, apatinib, cabotinib (XL-184), multi-vitamin tinib, lenvatinib, mo Taisha ni, niladinib, ponatinib, lei Gela non-ni, statinib (sitravatinib) (MGCD 516), sunitinib, sorafenib, valatinib, vandetanib, AUY-922 (5- (2, 4-dihydroxy-5-isopropyl-phenyl) -N-ethyl-4- [4- (morpholinomethyl) phenyl ] isoxazole-3-carboxamide), BLU6864, BLU-667, DCC-2157, NVP-AST487 (1- [4- [ (4-ethylpiperazin-1-yl) methyl ] -3- (trifluoromethyl) phenyl ] -3- [4- [6- (methylamino) pyrimidin-4-yl ] oxyphenyl ] urea), PZ-1, RPI-1 (1, 3-dihydro-5, 6-dimethoxy-3- [ (4-hydroxyphenyl) methylene ] -1H-indol-2-one), RXDX-105 (1- (3- (6, 7-dimethoxyquinazolin-4-yl) oxy) phenyl) -3- (5- (1, 1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea, SPP86 (1-isopropyl-3- (phenylethynyl) -1H-pyrazolo [3,4-d ] pyrimidin-4-amine) and TG101209 (N- (1, 1-dimethylethyl) -3- [ [ 5-methyl-2- [ [4- (4-methyl-1-piperazinyl) phenyl ] amino ] -4-pyrimidinyl ] amino ] benzenesulfonamide).
Other therapeutic agents include RET inhibitors such as those described, for example, in U.S. Pat. Nos. 7,504,509, 8,299,057, 8,399,442, 8,067,434, 8,937,071, 9,006,256, and 9,035,063, U.S. publication No. 2014/0121239;20160176865;2011/0053934;2011/0301157;2010/0324065;2009/0227556;2009/0130229;2009/0099167;2005/0209195; International publication Nos. WO 2014/184069;WO 2014/072220;WO2012/053606;WO 2009/017838;WO 2008/031551;WO 2007/136103;WO 2007/087245;WO2007/057399;WO 2005/051366;WO 2005/062795; and WO 2005/044835, and J.Med. Chem.2012,55 (10), 4872-4876, all of which are incorporated herein by reference in their entirety.
The present invention also provides a method of treating cancer comprising administering to a patient in need thereof a pharmaceutical combination comprising (a) a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (b) other therapeutic agents, and (c) optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use in treating cancer, wherein the amount of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and the amount of the other therapeutic agents are co-effective in treating cancer.
The compounds and compositions of the invention may be administered alone or in combination with other compounds (including other RET modulating compounds) or other therapeutic agents. In some embodiments, a compound or composition of the invention may be administered in combination with one or more compounds selected from the group consisting of Cabozantine (COMETRIQ), vandetanib (CALPRESA), sorafenib (NEXAVAR), sunitinib (SUTENT), lei Gela non-ni (STAVARGA), plaitinib (ICLUSIG), bevacizumab (avastin), crizotinib (XALKORI), or gefitinib (IRESSA). The compounds or compositions of the invention may be administered simultaneously or sequentially with other therapeutic agents by the same or different routes of administration. The compounds of the invention may be included with other therapeutic agents in a single formulation or in separate formulations.
In some embodiments, the compounds of the present invention may be used to treat Irritable Bowel Syndrome (IBS) in combination with one or more other therapeutic agents or therapies that are effective in the treatment of irritable bowel syndrome by acting through the same or different mechanisms of action. The at least one additional therapeutic agent may be administered with the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as part of the same or separate dosage form, via the same or different route of administration, and according to the same or different administration schedule, according to standard pharmaceutical practice known to those skilled in the art. Non-limiting examples of other therapeutic agents for the treatment of Irritable Bowel Syndrome (IBS) include probiotics, fiber supplements (e.g. psyllium, methylcellulose), antidiarrheals (e.g. loperamide), bile acid binders (e.g. cholestyramine, colestipol, colesevelam), anticholinergic and anticonvulsants (e.g. hyoscyamine, dicyclomine), antidepressants (e.g. tricyclic antidepressants such as imipramine or nortriptyline or selective 5-hydroxytryptamine reuptake inhibitors (SSRI) such as fluoxetine or paroxetine), antibiotics (e.g. rifaximin), alosetron and lubiprostone.
Use of the compounds and pharmaceutical compositions of the invention
The invention also provides the use of a compound of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for the prevention or treatment of a RET related disease or disorder, wherein the RET related disease or disorder comprises RET related cancer, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
The present invention provides compounds of the invention or pharmaceutical compositions thereof that inhibit RET wild-type and RET mutants, e.g., RET mutants that are resistant to current standard of care treatment ("RET resistant mutants"). In addition, the compounds of the present invention or pharmaceutical compositions thereof have inhibitory selectivity for both RET wild-type and RET gene mutants over other kinases, resulting in reduced toxicity associated with inhibition of other kinases.
The invention provides application of the compound or the pharmaceutical composition thereof for inhibiting RET wild type and RET mutant in preparing medicines for preventing or treating RET wild type and RET mutant related diseases or symptoms.
In some embodiments of any of the methods or uses described herein, the cancer (e.g., RET related cancer) is a hematologic cancer. In some embodiments of any of the methods or uses described herein, the cancer (e.g., RET related cancer) is a solid tumor. In some embodiments of any of the methods or uses described herein, the cancer (e.g., RET related cancer) is lung cancer (e.g., small cell lung cancer or non-small cell lung cancer), papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, lung adenocarcinoma, bronchiolar lung cancer, multiple endocrine tumor type 2A or type 2B (MEN 2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer (e.g., metastatic colorectal cancer), papillary renal cell carcinoma, gangliocytomatosis of the gastrointestinal mucosa, inflammatory myofibroblastic tumor, or cervical cancer. In some embodiments of any of the methods or uses described herein, the cancer (e.g., RET-associated cancer) is selected from the group consisting of Acute Lymphoblastic Leukemia (ALL), acute Myelogenous Leukemia (AML), juvenile cancer, adrenocortical cancer, anal cancer, Appendix cancer, astrocytoma, atypical teratoma/rhabdoid tumor, basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchogenic tumor, burkitt's lymphoma, carcinoid tumor, unknown primary carcinoma, heart tumor, cervical cancer, childhood cancer, chordoma, chronic Lymphocytic Leukemia (CLL), chronic Myelogenous Leukemia (CML), chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngeal pipe tumor, cutaneous T-cell lymphoma, cholangiocarcinoma, ductal carcinoma in situ, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, sensoroblastoma, ewing sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic cholangiocarcinoma, eye cancer, fallopian tube cancer, bone fibrous histiocytoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic disease, glioma, hairy cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular carcinoma, histiocytosis, hodgkin lymphoma, hypopharynx cancer, intraocular melanoma, islet cell tumor, pancreatic neuroendocrine tumor, kaposi sarcoma, kidney cancer, langerhans' histiocytosis, laryngeal cancer, leukemia, lip and mouth cancer, liver cancer, lung cancer, lymphoma, macroglobulinemia, bone malignant fibrous histiocytoma, bone cancer, melanoma, merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer, midline carcinoma, oral cancer, multiple endocrine tumor syndrome, multiple myeloma, mycosis granuloma, myelodysplastic syndrome, myelodysplasia/myeloproliferative neoplasm, myelogenous leukemia, multiple myeloma, myeloproliferative neoplasms, nasal and sinus cancers, nasopharyngeal cancers, neuroblastomas, non-hodgkin's lymphoma, non-small cell lung cancer, oral cancer, lip cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancers, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary cancer, plasmacytoma, pleural-pulmonary blastoma, pregnancy and breast cancer, primary central nervous system lymphoma, primary peritoneal cancer, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, sarcoma, szebra's syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer, gastric cancer, T-cell lymphoma, testicular cancer, pharyngeal cancer, thymus and thymus cancer, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, unknown primary cancer, carcinoma of the urinary tract, carcinoma, wilm's tumor of the uterus, uterine tumor, wilm's tumor, carcinoma of the uterus, and the uterus.
In some embodiments, the RET related cancer of the present invention is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine tumors of type 2A or 2B (MEN 2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal gangliocytoma, and cervical cancer. In some embodiments, the RET related cancer is RET fusion lung cancer or medullary thyroid cancer.
In some embodiments, the compounds of formula (I), (I-1), (I-2), or (I-3), and pharmaceutically acceptable salts and solvates thereof, are useful in treating patients suffering from RET inhibitor resistance mutations that result in increased resistance to compounds or pharmaceutically acceptable salts or solvates other than those of formula (I), (I-1), (I-2), (I-3), or (I-4), e.g., substitution at amino acid position 804, e.g., V804M, V804L or V804E), by co-administration or as a subsequent treatment of existing medications (e.g., other RET kinase inhibitors other than those of formula (I), (I-1), (I-2), or (I-3), or pharmaceutically acceptable salts or solvates thereof). Exemplary RET kinase inhibitors (e.g., other RET kinase inhibitors that are not compounds of formula (I), (I-1), (I-2), or (I-3), or pharmaceutically acceptable salts or solvates thereof) are described. In some embodiments, the RET kinase inhibitor may be selected from the group consisting of cabotinib, vandetanib, alatinib, sorafenib, lenvatinib, pluratinib, multi-vitamin tinib, sunitinib, fortinib (foretinib), BLU667, and BLU6864.
In some embodiments of any of the methods or uses described herein, the Irritable Bowel Syndrome (IBS) comprises diarrhea predominant, constipation predominant, or alternating, functional abdominal distension, functional constipation, functional diarrhea, unspecific functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disease, functional gastroduodenal disease, functional anorectal pain, and inflammatory bowel disease.
The compounds and compositions according to the methods of the invention can be in any amount and by any route effective for treating or lessening the severity of the disease. The exact amount necessary will vary depending on the patient's condition, depending on the age, general condition of the patient, severity of the infection, particular factors, mode of administration, and the like. The compounds or compositions may be used in combination with one or more other therapeutic agents, as discussed herein.
General methods for the Synthesis of Compounds of the invention
In general, the compounds of the invention may be prepared by the methods described herein, unless otherwise indicated, wherein the substituents are as defined in formula (I), (I-1), (I-2) or (I-3). The following reaction schemes and examples are provided to further illustrate the present invention.
Those skilled in the art will recognize that the chemical reactions described herein can be used to suitably prepare many other compounds of the present invention, and that other methods for preparing the compounds of the present invention are considered to be within the scope of the present invention. For example, the synthesis of those non-exemplified compounds according to the invention can be successfully accomplished by modification methods, such as appropriate protection of interfering groups, by use of other known reagents in addition to those described herein, or by some conventional modification of the reaction conditions, by those skilled in the art. In addition, the reactions disclosed herein or known reaction conditions are also well-known to be applicable to the preparation of other compounds of the present invention.
The examples described below are given unless otherwise indicated that all temperatures are given in degrees celsius. Unless otherwise indicated, reagents were commercially available, e.g., reagents were purchased from commercial suppliers such as Ling Kai medicine, ALDRICH CHEMICAL Company, inc., arco Chemical Company and ALFA CHEMICAL Company, and were used without further purification unless otherwise indicated. The general reagents were purchased from Shandong Chemicals, guangdong Chemicals, guangzhou Chemicals, tianjin Chemie, inc., qingdao Tenglong chemical Co., ltd., and Qingdao ocean chemical works.
The anhydrous tetrahydrofuran is obtained by reflux drying of metallic sodium. The anhydrous methylene chloride and chloroform are obtained by reflux drying of calcium hydride. Ethyl acetate, N-dimethylacetamide and petroleum ether were dried over anhydrous sodium sulfate in advance for use.
The following reaction is typically carried out under nitrogen or argon pressure or with a dry tube (unless otherwise indicated) over anhydrous solvent, the reaction flask is capped with a suitable rubber stopper and the substrate is injected through a syringe. The glassware was all dried.
The chromatographic column is a silica gel column. Silica gel (300-400 mesh) was purchased from Qingdao ocean chemical plant. Nuclear magnetic resonance spectroscopy was performed using CDC1 3 or DMSO-d 6 as a solvent (reported in ppm) and TMS (0 ppm) or chloroform (7.25 ppm) as reference standards. When multiple peaks occur, the abbreviations s (singlet ), d (doublet, doublet), t (triplet ), m (multiplet, multiplet), br (broadened, broad), dd (doublet of doublets, doublet), dt (doublet of triplets, doublet) will be used. Coupling constant J, expressed in hertz (Hz).
Low resolution Mass Spectrometry (MS) data were determined by a spectrometer of the Agilent6320 series LC-MS equipped with a G1312A binary pump and a G a 1316A TCC (column temperature maintained at 30 ℃) for analysis, a G1329A autosampler and a G1315B DAD detector for analysis, and an ESI source for LC-MS spectrometer.
Low resolution Mass Spectrometry (MS) data were determined by a spectrometer of the Agilent6120 series LC-MS equipped with a G1311A quaternary pump and a G1316A TCC (column temperature maintained at 30 ℃), a G1329A autosampler and a G1315D DAD detector were applied for analysis, and an ESI source was applied to the LC-MS spectrometer.
Both spectrometers were equipped with Agilent Zorbax SB-C18 columns, 2.1X130 mm,5 μm in size. The injection volume was determined by the sample concentration, the flow rate was 0.6mL/min, and the peak of the HPLC was recorded by UV-Vis wavelengths at 210nm and 254 nm. The mobile phase was a 0.1% acetonitrile formate solution (phase a) and a 0.1% ultrapure formate solution (phase B).
Compound purification was assessed by Agilent 1100 series High Performance Liquid Chromatography (HPLC), with UV detection at 210nm and 254nm, a Zorbax SB-C18 column, specification 2.1 x 30mm,4 μm,10 min, flow rate 0.6mL/min,5-95% (0.1% formic acid in acetonitrile) of 0.1% formic acid in water, column temperature maintained at 40 ℃.
The following abbreviations are used throughout the present invention:
TEA triethylamine
DMF N, N-dimethylacetamide
NaH sodium hydride
DIPEA N, N-diisopropylethylamine
EDCI 1-ethyl-3 (3-dimethylpropylamine) carbodiimide
DMAC N, N-dimethylacetamide
DMAP 4-dimethylaminopyridine
DMSO dimethyl sulfoxide
HATU 2- (7-azobenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate
DCM dichloroethane
EA ethyl acetate
PE Petroleum ether
MeOH methanol
MeOD deuterated methanol
NaOH sodium hydroxide
NH 4 Cl ammonium chloride
K 2CO3 Potassium carbonate
THF tetrahydrofuran
N-BuLi n-butyllithium
Boc
OMs methanesulfonyloxy
Mass%,% mass%
ML of
L liter (L)
Mmol millimoles
M, mol/L
G
Min
H hours
Degree C
TLC thin layer chromatography
The following synthetic schemes describe the steps for preparing the disclosed compounds. Each R 1、R2、X1、X2、X3、X4、X5, T, E, A, Q and M has the definition as described herein unless otherwise indicated.
Scheme for the synthesis of intermediate (Ia)
The synthesis of the intermediate (Ia) can be obtained by reference to the synthetic steps of the above synthesis scheme of the intermediate (Ia). Wherein Hal 1 is F, cl, br or I, preferably Cl or Br, hal 2 is F, cl, br or I, preferably F, cl or Br, alk is C 1-6 alkyl, preferably C 1-4 alkyl, more preferably methyl, ethyl, isopropyl or tert-butyl. The compound (Ia-1) is reacted with a metal hydroxide (such as sodium hydroxide) under a proper condition (such as dodecyl mercaptan, water and N, N-dimethylacetamide are present) to obtain a compound (Ia-2), the compound (Ia-2) is reacted with trifluoroacetic anhydride under a proper condition (such as pyridine) to obtain a compound (Ia-3), the compound (Ia-3) is reacted with the compound (Ia-4) under a proper coupling agent condition (such as palladium coupling agent, preferably [1,1 '-bis (diphenylphosphine) ferrocene ] dichloropalladium dichloromethane complex) under a proper solvent (such as dioxane, etc.) to obtain a compound (Ia-5), the compound (Ia-5) is reacted with the compound (Ia-6) under a proper coupling agent condition (such as palladium coupling agent, preferably [1,1' -bis (diphenylphosphine) ferrocene ] dichloropalladium dichloromethane complex) under a proper solvent (such as toluene, etc.) to obtain a compound (Ia-7), and the compound (Ia-7) is reacted with sodium hydroxide under a proper solvent (such as tetrahydrofuran) to obtain a compound (Ia-7) under a proper condition (such as tetrahydrofuran).
Scheme for the synthesis of intermediate (Ib)
The intermediate compound represented by the formula (Ib) can be obtained by referring to the synthetic procedure of the above intermediate (Ib) synthesis scheme. Hal 1 and Hal 2 are each independently F, cl, br or I, preferably Cl or Br, pg 1 is an amino protecting group, such as Boc, etc., pg 2 is a hydroxy protecting group, such as benzyl, etc., and ring A a is A3-12 membered heterocyclylene group in which at least two ring atoms are nitrogen atoms. The compound of formula (Ia) and the compound of formula (Ib-1) are subjected to coupling reaction to obtain the compound of formula (Ib-2), the compound of formula (Ib-2) and the compound of formula (Ib-3) are reacted under alkaline conditions to obtain the compound of formula (Ib-4), the compound of formula (Ib-4) is deaminated and protected under acidic conditions to obtain the compound of formula (Ib-5) or a salt of the compound of formula (Ib-5), the compound of formula (Ib-5) or the salt of the compound of formula (Ib-5) and the compound of formula (Ib-6) are reacted under alkaline conditions to obtain the compound of formula (Ib-7), and the compound of formula (Ib-7) is reduced under proper conditions (such as H 2 and Pd/C).
Scheme for the synthesis of intermediate (Ic)
The intermediate compound of formula (Ic) can be obtained by reference to the synthetic steps of the above intermediate (Ic) synthesis scheme. Wherein Hal 2 is F, cl, br or I, preferably Cl or Br, and ring A b is A3-12 membered heterocyclylene group in which at least one ring atom is a nitrogen atom. The compound of formula (Ia) is coupled with a compound of formula (Ic-1) or a salt of a compound of formula (Ic-1) (e.g., hydrochloride, formate, etc.) under suitable conditions (e.g., in DMSO solvent, under basic conditions, such as K 2CO3) to provide a compound of formula (Ic).
Synthesis scheme 1
Compound (IA) can be obtained by referring to the synthetic procedure of synthesis scheme 1. Wherein Hal 2 is F, cl, br or I, preferably F, cl or Br, and ring A b is a 3-12 membered heterocyclylene group in which at least one ring atom is a nitrogen atom. The compound (Ia) is coupled with the compound (Ia-1) under proper conditions (such as in an N, N-dimethylacetamide solvent and under alkaline conditions such as K 2CO3) to obtain the compound (Ia-2), and the compound (Ia-2) is coupled with the compound (Ic-1) or a salt (such as hydrochloride, formate, trifluoroacetate, etc.) of the compound (Ic-1) under proper conditions (such as in a DMSO solvent and under alkaline conditions such as K 2CO3) to obtain the compound (Ia).
Synthesis scheme 2
Compound (IAA) can be obtained by reference to the synthetic procedure of synthesis scheme 2. Wherein Hal 1 is F, cl, br or I, preferably Cl or Br. The compound (Id) is coupled with the compound (IA-1) under suitable conditions (e.g., in N, N-dimethylacetamide solvent, under basic conditions such as K 2CO3) to give the compound (IAA).
Synthesis scheme 3
Compound (IAA) can be obtained by reference to the synthetic procedure of synthesis scheme 3. The compound (Id) is coupled with the compound (IA-3) under suitable conditions (e.g., in N, N-dimethylformamide solvent, under basic conditions such as K 2CO3) to give the compound (IAA).
Synthesis scheme 4
Compound (IA) can be obtained by reference to the synthetic procedure of synthesis scheme 4. Wherein Hal 2 is F, cl, br or I, preferably F, cl or Br, and ring A b is a 3-12 membered heterocyclylene group in which at least one ring atom is a nitrogen atom. The compound (Ia) is coupled with the compound (Ia-3) under proper conditions (such as in an N, N-dimethylformamide solvent and under alkaline conditions such as K 2CO3) to obtain the compound (Ia-2), and the compound (Ia-2) is coupled with the compound (Ic-1) or a salt (such as hydrochloride, formate, trifluoroacetate, etc.) of the compound (Ic-1) under proper conditions (such as in a DMSO solvent and under alkaline conditions such as K 2CO3) to obtain the compound (Ia).
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Intermediate 1:4- (6-fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 6-bromo-4-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile
6-Bromo-4-methoxypyrazolo [1,5-a ] pyridine-3-carbonitrile (50 g,198.36 mmol), water (16.5 mL, 912 mmol), sodium hydroxide (16.03 g,396.8 mmol) and DMAE (500 mL) were added sequentially to a 1L single-necked flask at room temperature, stirred at room temperature for 5min, then dodecyl mercaptan (97 mL,397 mmol) was slowly added at 0℃and after the addition was completed the reaction was transferred to 45℃overnight. The reaction solution was poured into 3L of ice water, and saturated aqueous citric acid solution was slowly added to adjust ph=5, stirred for half an hour, then allowed to stand, filtered, and the filter cake was washed with water and petroleum ether several times, and dried at 60 ℃ to obtain 44.1g of a yellow solid, which was the target product (yield 93.4%). LC-MS (ES-API) m/z=239.05 [ M+H ] +.
Step 2 6-bromo-3-cyanopyrazolo [1,5-a ] pyridin-4-yl triflate
To a 1L single vial was added 6-bromo-4-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile (44.1 g,185 mmol), pyridine (45 mL,559 mmol), DCM (800 mL), the temperature was reduced below-10℃and trifluoromethanesulfonic anhydride (50 mL,297.2 mmol) was slowly added, and after stirring for 1h, the reaction was allowed to spontaneously warm to room temperature overnight. The DCM was dried under reduced pressure, diluted with water (250 mL), extracted with EA (500 mL. Times.3), the organic phase was collected, washed with saturated brine (250 mL), dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (eluent: PE/EA (v/v) =50/1-25/1) to give 61.5g of the title product as a yellow-like solid in 89.7% yield.
Step 3 6-bromo-4- (6-fluoropyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
6-Bromo-3-cyanopyrazolo [1,5-a ] pyridin-4-yl trifluoromethanesulfonate (61.5 g,166 mmol), 2-fluoropyridine-5-borate (44.5 g,200 mmol), a [1,1' -bis (diphenylphosphine) ferrocene ] palladium dichloride dichloromethane complex (6.8 g,8.3 mmol), 1, 4-dioxane (850 mL) were added to a 1L three-necked flask under nitrogen, the temperature was reduced to-10℃and potassium acetate solution (115 mL,345mmol,3 mol/L) was slowly added, and after stirring at this temperature for 1h, the reaction was continued at room temperature overnight. Filtering, washing filter cake with EA (500 mL×3), washing the filtrate with water (500 mL), washing the filtrate with saturated saline (250 mL), drying with anhydrous sodium sulfate, filtering, spin-drying the filtrate, purifying by silica gel column chromatography (eluent: PE/DCM (v/v) =2/1-0/1), to obtain 49g of white solid, namely the target product, yield 93.0％.LC-MS(ES-API):m/z＝318.10[M+H]+;1H NMR(400MHz,DMSO-d6)δ9.49(d,J＝1.2Hz,1H),8.73(s,1H),8.51(d,J＝1.9Hz,1H),8.27(td,J＝8.2,2.5Hz,1H),7.86(d,J＝1.2Hz,1H),7.40(dd,J＝8.4,2.5Hz,1H).
Step 4- (6-Fluoropyridin-3-yl) -6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
6-Bromo-4- (6-fluoropyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (8 g,25.23 mmol), pinacol ester (10 g,39.39 mmol), potassium acetate (10 g,101.9 mmol), redistilled toluene (150 mL), bubbling for another 10min after nitrogen substitution, and [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride dichloromethane complex (2.1 g,2.6 mmoles) were sequentially added under nitrogen protection to the flask, and the reaction was heated at 120℃overnight after bubbling for 10min with nitrogen substitution. Filtering with diatomite, washing (50 mL×3) filter cake with EA, washing the organic phase with saturated salt water (250 mL), drying with anhydrous sodium sulfate, filtering, spin-drying, purifying with silica gel column chromatography (eluent: PE/DCM (v/v) =2/1-0/1), collecting spin-drying to obtain 8.5g of orange solid, which is the target product (yield) 93.0％).1H NMR(400MHz,CDCl3)δ8.99(s,1H),8.43(d,J＝2.1Hz,1H),8.34(s,1H),8.02(td,J＝8.0,2.5Hz,1H),7.66(s,1H),7.13(dd,J＝8.5,2.8Hz,1H),1.40(s,12H).
Step 5 4- (6-Fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 250mL single flask were successively added 4- (6-fluoropyridin-3-yl) -6- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (8.5 g,23 mmol) and tetrahydrofuran (120 mL), and under ice-bath conditions, sodium hydroxide solution (60 mL,120mmol,2 mol/L) and hydrogen peroxide (14 mL,140mmol, content 30%) were slowly added and stirred at low temperature. After completion of the TLC monitoring, a sodium thiosulfate solution (50 mL,150mmol,3 mol/L) was slowly added, and after returning to room temperature, water (250 mL), EA extraction (250 mL. Times.2) was performed, and the organic phases were combined and washed with a 0.1M NaOH solution (500 mL. Times.2). All aqueous phases were combined, the pH was adjusted to 4 with dilute hydrochloric acid, stirred at room temperature for 15min, and suction filtered to give a wet cake. The mother liquor EA was extracted (250 mL. Times.3), all organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried and purified by column chromatography on silica gel (eluent: DCM/MeOH (v/v) =100/0-100/1) to give a pale yellow solid. Combining all solids, oven drying at 50deg.C to give pale yellow solid 5.1g as target product (yield 86.0％).LC-MS(ES-API):m/z＝255.10[M+H]+;1H NMR(400MHz,DMSO-d6)δ10.44-10.37(m,1H),8.54(s,1H),8.49-8.46(m,1H),8.42-8.40(m,1H),8.26-8.21(m,1H),7.40-7.35(m,1H),7.32-7.30(m,1H).
Intermediate 2:4- (6- (3, 6-diazabicyclo [3.1.1] hept-3-yl) pyridin-3-yl) -6- (benzyloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile dihydrochloride
Step 1 3- (5- (3-cyano-6-hydroxypyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester
To a 30mL microwave tube, 4- (6-fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,1.5g,5.9 mmol), 6- (t-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane (2.3 g,12 mmol), N, N-diisopropylethylamine (2.0 mL,12 mmol), dimethyl sulfoxide (15 mL) was added sequentially, and the reaction was sealed and carried out under microwave 80℃for 8 hours. Under low temperature conditions, water (50 mL) was added for dilution, EA extraction (100 mL. Times.5), the combined organic phases were washed with saturated brine (250 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried and purified by silica gel chromatography (eluent: PE/EA (v/v) =5/1-1/1.5), followed by collection to give 1.9g of a yellow product as the objective product (yield 74.0%). LC-MS (ES-API): m/z=433.10 [ m+h ] +.
Step 2 3- (5- (6- (benzyloxy) -3-cyanopyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester
In a 25mL single vial was added tert-butyl 3- (5- (3-cyano-6-hydroxypyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylate (1 g,2.31 mmol), benzyl bromide (0.302 mL,2.54 mmol), potassium carbonate (0.97 g,6.93 mmol), N, N-dimethylformamide (10 mL), and stirred at 80℃overnight. Quenching with saturated ammonium chloride (100 mL) at room temperature, extracting with DCM (100 mL×3), mixing the organic phases, drying over anhydrous sodium sulfate, filtering, spin-drying the filtrate, purifying the residue with silica gel column chromatography (eluent PE/EA (v/v) =5/1-2/1) to obtain 1.06g of yellow solid as the target product (yield) 87.7％).LC-MS(ES-API):m/z＝523.30[M+H]+;1H NMR(400MHz,CDCl3)δ8.37(s,1H),8.19(s,1H),8.17(d,J＝1.9Hz,1H),7.74(d,J＝8.7Hz,2H),7.42(dt,J＝11.9,7.4Hz,5H),7.18(d,J＝2.0Hz,1H),5.13(s,2H),4.31(d,J＝4.0Hz,2H),4.16(dd,J＝8.7,4.4Hz,2H),3.55(dd,J＝8.1,3.1Hz,2H),2.24–2.20(m,1H),2.01(d,J＝5.5Hz,1H),1.38(s,9H).
Step 3 4- (6- (3, 6-diazabicyclo [3.1.1] hept-3-yl) pyridin-3-yl) -6- (benzyloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile dihydrochloride
3- (5- (6- (Benzyloxy) -3-cyanopyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester (1.06 g,2.03 mmol) and ethyl acetate hydrochloride solution (5 mL,20mmol,4 mol/L) were mixed and reacted overnight at room temperature. The reaction solution was spin-dried to give a yellow viscous material, which was dried at 60℃to give 1.0g of a yellow solid as the objective product (yield 100%). LC-MS (ES-API) m/z=423.30 [ M-2HCl ] +.
Intermediate 3:5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride
Step 1:3- ((methylsulfonyl) oxy) azetidine-1-carboxylic acid tert-butyl ester
N-Boc-3-hydroxyazetidine (4.00 g,23.1 mmol) was dissolved in DCM (50 mL) in a 100mL single-necked flask under ice-bath conditions, et 3 N (4.66 g,46.1 mmol) was slowly added, stirred for 10min, methanesulfonyl chloride (2.91 g,25.4 mmol) was slowly added, and the reaction was allowed to warm to room temperature with stirring for 2h. TLC showed the reaction was complete. Slowly adding water for quenching reaction, extracting with DCM (20 mL×3), washing with saturated NaHCO 3 solution (40 mL), drying with anhydrous sodium sulfate, filtering, spin-drying the filtrate, purifying with silica gel column chromatography (eluent: PE/EA (v/v) =8/1-3/1), to obtain colorless viscous liquid 4.41g (yield 76%) as target product .1H NMR(400MHz,CDCl3)δ5.23–5.12(m,1H),4.30–4.19(m,2H),4.10–4.03(m,2H),3.04(s,3H),1.42(s,9H).
Step 2 3- ((6-methoxypyridin-3-yl) oxy) azetidine-1-carboxylic acid tert-butyl ester
In a 100mL single-necked flask, 5-hydroxy-2-methoxypyridine (2.00 g,16.0 mmol) and tert-butyl 3- ((methylsulfonyl) oxy) azetidine-1-carboxylate (4.82 g,19.2 mmol) were dissolved in DMF (30 mL), t-BuOK (3.59 g,32.0 mmol) was slowly added, stirred for 10min and then warmed to 50℃and reacted for 12h with stirring. TLC showed that the reaction was completed, cooled to room temperature, washed with 150mL of water, extracted with EA (300 mL. Times.2), and the combined organic phases were washed with 100mL of water, dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin-drying. Purifying the residue by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-4/1) to obtain yellow brown solid 2.03g as target product (yield) 45％).LC-MS(ES-API):m/z＝281.3[M+H]+;1HNMR(400MHz,CDCl3)δ7.57(d,J＝2.9Hz,1H),7.17-7.06(m,1H),6.67(d,J＝8.9Hz,1H),4.85-4.75(m,1H),4.30-4.19(m,2H),4.00-3.93(m,2H),3.85(s,3H),1.42(s,9H).
Step 3 5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride
In a 25mL single-necked flask, tert-butyl 3- ((6-methoxypyridin-3-yl) oxy) azetidine-1-carboxylate (280 mg,1.00 mmol) and ethyl acetate hydrochloride solution (5 mL,20mmol,4 mol/L) were added and the mixture was stirred at room temperature to react for 2h. TLC showed that the reaction was complete, dried directly by spin-drying, and dried in a dry box at 60℃to give 0.21g of a tan solid. LC-MS (ES-API) m/z=181.10 [ M-HCl+H ] +.
Intermediate 4:6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 (6-methoxypyridin-3-yl) methanol
To a 25mL single flask was added 6-methoxy-3-pyridinecarbaldehyde (0.4 g,3 mmol), lithium aluminum tetrahydride (0.06 g,2 mmol) and tetrahydrofuran (10 mL) in sequence at 0deg.C, and the temperature was allowed to react overnight. EA (50 mL) was added, the reaction mixture was diluted with water (50 mL), the organic phase was separated by extraction, the organic phase was washed with a saturated NH 4 Cl (50 mL) solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin-drying, followed by purification on a silica gel column (eluent: DCM/EA (v/v) =4/1) to give 0.38g of the target product (yield) 90.0％).LC-MS(ES-API):m/z＝140.15[M+H];1H NMR(400MHz,CDCl3)δ8.12(d,J＝1.8Hz,1H),7.62(dd,J＝8.5,2.4Hz,1H),6.75(d,J＝8.5Hz,1H),4.62(s,2H),3.93(s,3H).
Step 2 5- (bromomethyl) -2-methoxypyridine
In a 25mL single-necked flask, (6-methoxypyridin-3-yl) methanol (0.38 g,2.7 mmol), methylene chloride (8 mL), and phosphorus tribromide (0.31 mL,3.3 mmol) were sequentially added, and reacted at 0℃for 30min. DCM (25 mL) was added for dilution, saturated aqueous K 2CO3 (25 mL) was washed, the organic phase dried over anhydrous sodium sulfate, filtered, and the filtrate was dried and taken directly to the next step without further purification.
Step 36- (benzyloxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 25mL single vial was added 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (benzyloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile dihydrochloride (400 mg,0.81 mmol), potassium carbonate (0.34 g,2.42 mmol), N, N-dimethylformamide (8 mL), followed by slow addition of 5- (bromomethyl) -2-methoxypyridine (0.50 g,2.5 mmol) and stirring overnight at room temperature. The reaction solution was diluted with water (25 mL), extracted with EA (50 ml×3), washed with saturated organic phase brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried, and purified by silica gel chromatography (eluent: DCM/MeOH (v/v) =1/0-20/1) to give 0.29g of a pale yellow solid as the target product (yield) 65.82％).LC-MS(ES-API):m/z＝544.10[M+H]+;1H NMR(400MHz,CDCl3)δ8.39(s,1H),8.22-8.17(m,2H),8.11(s,1H),8.02(s,1H),7.78(d,J＝8.8Hz,1H),7.42(dd,J＝14.9,7.1Hz,5H),7.19(s,1H),6.70(dd,J＝13.9,8.5Hz,2H),5.13(s,2H),3.92(s,3H),3.80(s,4H),3.59(s,4H),2.22(s,1H),2.01(s,1H).
Step 4 6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 50mL single vial was added 6- (benzyloxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (0.29 g,0.530 mmol), methanol (5 mL), palladium on carbon (0.03 g, content 10%) and after several hydrogen substitutions, stirred at room temperature overnight. Filtering the reaction solution, flushing a filter cake with methanol, and spin-drying the filtrate to obtain 240mg of light yellow solid which is the target product .LC-MS(ES-API):m/z＝454.30[M+H]+;1H NMR(400MHz,CDCl3)δ8.39(d,J＝1.7Hz,1H),8.28(d,J＝2.0Hz,1H),8.21(s,1H),8.17–8.12(m,1H),7.81(dd,J＝8.1,2.2Hz,2H),7.14(s,1H),6.78(d,J＝8.6Hz,1H),6.70(d,J＝8.3Hz,1H),5.37(s,1H),4.00-3.90(m,5H),3.73(s,4H),3.51(s,2H),2.27–2.21(m,1H),2.03(d,J＝6.6Hz,1H).
Intermediate 5:6-hydroxy-4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step1 4-hydroxy-4- (pyridin-2-ylmethyl) piperidine-1-carboxylic acid tert-butyl ester
50ML double-necked flask was charged with THF (9 mL) and 2-methylpyridine (0.640 mL,6.52 mmol) under nitrogen protection, a solution of n-BuLi in n-hexane (2.2 mL,5.5mmol,2.5 mol/L) was slowly added at 78℃and after 45min the reaction was transferred to room temperature for 2h, and a solution of tert-butyl 4-oxopiperidine-1-carboxylate (1 g,5.019 mmol) in THF (6 mL) was then added at-78 ℃. After the addition, the reaction is continued for 2 hours, and then the mixture is placed at room temperature for 2 hours. The reaction mixture was quenched with saturated ammonium chloride solution (10 mL), extracted with EA (30 mL. Times.2), and the organic phase was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and dried. Purification by silica gel column chromatography (eluent: PE/EA (v/v=10/1-1/1) gave 1.176g (yield 80.14%) of a pale yellow oil as the target product .LC-MS(ES-API):m/z＝293.40[M+H]+;1H NMR(400MHz,CDCl3)δ8.49–8.44(m,1H),7.61(td,J＝7.7,1.7Hz,1H),7.15(dd,J＝7.0,5.4Hz,1H),7.09(d,J＝7.7Hz,1H),3.76(s,2H),3.72–3.61(m,1H),3.21(s,2H),2.87(s,2H),1.47(d,J＝3.2Hz,4H),1.42(s,9H).
Step 24- (pyridin-2-ylmethyl) piperidin-4-yl hydrochloride
In a 25mL single-necked flask, tert-butyl 4-hydroxy-4- (pyridin-2-ylmethyl) piperidine-1-carboxylate (550 mg,1.89 mmol) and ethyl acetate hydrochloride solution (10 mL,40mmol,4 mol/L) were added and the mixture was stirred at room temperature for 3h. TLC shows that the reaction is finished, the reaction liquid is directly dried by spin to obtain yellow oily matter, and the yellow oily matter is put into an oven for drying at 60 ℃ to obtain 0.430g of theoretical yellow solid, namely the target product. LC-MS (ES-API): m/z=193.40 [ m+h ] +.
Step 3 6-hydroxy-4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 10mL microwave tube was added 4- (2-pyridylmethyl) piperidine-4-ol hydrochloride (430 mg,1.88 mmol), 4- (6-fluoro-3-pyridyl) -6-hydroxy-pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 2,240mg,0.94 mmol), potassium carbonate (522 mg,3.78 mmol), DMSO (2.4 mL) and the reaction was heated by microwave 85℃for 6h. TLC showed that the reaction was completed, the reaction solution (12 mL) was diluted with water, extracted with EA (30 mL. Times.2), and the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and spun-dried. Purification by silica gel column chromatography (eluent: pure EA-EA/MeOH (v/v=50/1)) gave 0.19g (yield 47%) of a tan solid as the target product .LC-MS(ES-API):m/z＝427.20[M+H]+;1H NMR(400MHz,MeOD)δ8.46(d,J＝4.2Hz,1H),8.23(d,J＝2.8Hz,2H),8.18(d,J＝2.0Hz,1H),7.75(d,J＝5.5Hz,1H),7.70(dd,J＝9.0,2.6Hz,1H),7.34(d,J＝7.8Hz,1H),7.29–7.24(m,1H),7.12(d,J＝1.9Hz,1H),6.89(d,J＝8.9Hz,1H),4.06(d,J＝13.2Hz,2H),3.38(dd,J＝18.1,7.6Hz,2H),2.97(s,2H),1.77–1.69(m,2H),1.62(d,J＝13.3Hz,2H).
Intermediate 6:6-hydroxy-4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1:6-methoxy nicotinic acid
Sodium dihydrogen phosphate (1.1 mL,1.1mmol,1.0 mol/L) and hydrogen peroxide (0.41 mL,4.0mmol, content 30%) were adjusted to pH 2 with hydrochloric acid (12 mol/L) under ice bath conditions, 3- (6-methoxypyridin-3-yl) prop-2-yn-1-al (500 mg,3.65 mmol) dissolved in acetonitrile (4 mL) was then added, followed by three slow additions of sodium chlorite (803 mg,4.01 mmol) and stirring was continued under ice bath for 2h. The reaction solution was slowly returned to room temperature, diluted with water (50 mL), extracted with EA (100 mL. Times.3), combined with the organic phase, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated to give 554mg of a yellow solid as the target product (yield) ：99.26％).LC-MS(ES-API):m/z＝154.15[M+H]+;1H NMR(400MHz,CDCl3)δ8.91(d,J＝2.1Hz,1H),8.19(dd,J＝8.7,2.3Hz,1H),6.80(d,J＝8.7Hz,1H),4.02(s,3H).
Step 2 6- (benzyloxy) -4- (6- (6- (6-methoxy-nicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 25mL single vial was added 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (benzyloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile hydrochloride (intermediate 2,770mg,1.55 mmol), HATU (895 mg,2.33 mmol), 6-methoxynicotinic acid (284 mg,1.87 mmol), dimethyl sulfoxide (8 mL), triethylamine (1.0 mL,6.23 mmol) was slowly added and stirred overnight at room temperature. After the reaction, water (25 mL) was added to the reaction mixture, EA (50 mL. Times.3) was used for extraction, the organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated, followed by purification by silica gel column chromatography (eluent: DCM/MeOH (v/v=1/0-40/1) to give 550mg of a pale yellow solid as the target product (yield 63.0%). LC-MS (ES-API): m/z=558.30 [ M+H ] +.
Step 3 6-hydroxy-4- (6- (6- (6-methoxy nicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 50mL single port flask were successively added 6- (benzyloxy) -4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (0.55 g,0.99 mmol), methanol (5 mL), tetrahydrofuran (15 mL) and palladium on carbon (0.06 g, content 10%) and the mixture was stirred at room temperature overnight after hydrogen substitution several times. The reaction solution was filtered, the filter cake was rinsed with methanol, and the filtrate was dried by spin to give 0.4g of a pale yellow solid as the objective product (yield 90.0%). LC-MS (ES-API): m/z=468.10 [ m+h ] +.
EXAMPLE 1N- (1- (5- (3-cyano-6- (prop-2-yn-1-yloxy) pyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -4-methylpiperidin-4-yl) -2- (4-methoxyphenyl) acetamide
Step 1 4- (2- (4-methoxyphenyl) acetamido) -4-methylpiperidine-1-carboxylic acid tert-butyl ester
To a25 mL single flask was added tert-butyl 4-amino-4-methyl-piperidine-1-carboxylate (500 mg,2.33 mmol), DCM (10 mL), EDCI (0.67 g,3.5 mmol), HOBt (0.47 g,3.5 mmol), DIPEA (1.6 mL,9.7 mmol), 2- (4-methoxyphenyl) acetic acid (0.47 g,2.8 mmol), stirred at room temperature and monitored by TLC. The reaction was overnight and TLC showed complete reaction. The reaction mixture was taken up in water (15 mL), the organic phase was separated, the aqueous phase was extracted with DCM (20 mL. Times.2), the organic phases were combined, washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, filtered, the mother liquor was dried by spinning, and the residue was chromatographed on silica gel (eluent: PE/EA (v/v) =7/1-3/1) to give 0.82g of a transparent solid as the target product (yield) 97％).1H NMR(400MHz,CDCl3)δ7.15(d,J＝8.5Hz,2H),6.89(d,J＝8.6Hz,2H),5.07(s,1H),3.81(s,3H),3.62(s,2H),3.46(s,2H),2.81(t,J＝11.3Hz,2H),1.91(s,2H),1.71(s,2H),1.43(s,9H),1.35(s,3H).
Step 2- (4-methoxyphenyl) -N- (4-methylpiperidin-4-yl) acetamide 2, 2-trifluoroacetate
In a 50mL single vial containing tert-butyl 4- (2- (4-methoxyphenyl) acetamido) -4-methylpiperidine-1-carboxylate (0.82 g,2.3 mmol) was added DCM (9 mL) and TFA (3 mL) and the reaction stirred at room temperature overnight. TLC monitoring reaction is complete, the reaction liquid is directly dried by spin-drying the solvent, pumping is carried out, and a colorless transparent oily liquid product is obtained, and the yield is calculated according to 100%.
Step 3 4- (6-Fluoropyridin-3-yl) -6- (prop-2-yn-1-yloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 50mL single vial was added 4- (6-fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,0.2g,0.8 mmol), K 2CO3 (0.3 g,2 mmol) and DMAC (10 mL), 3-bromoprop-1-yne (0.1 mL,1 mmol) and reacted at 60℃overnight, with TLC monitoring the reaction. The reaction solution was cooled to room temperature naturally, added with NH 4OH/H2 O (v/v=1/1, 10 ml), stirred vigorously for 15min, the suspension obtained was filtered, and the filter cake was washed with a small amount of water to give a dark brown solid. Adding 2mL of methanol and 20mL of water into the solid, pulping at room temperature, filtering after 1h, washing a filter cake with a small amount of water, and drying at 50 ℃ in vacuum for 16h to obtain 0.17g of light brown solid, namely the target product (yield 70％).LC-MS(ES-API):m/z＝293.05[M+H]+;1H NMR(400MHz,DMSO-d6)δ8.83(s,1H),8.64(s,1H),8.50(s,1H),8.29-8.24(m,1H),7.59(s,1H),7.41-7.37(m,1H),5.01(s,2H),3.72(s,1H).
Step 4N- (1- (5- (3-cyano-6- (prop-2-yn-1-yloxy) pyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -4-methylpiperidin-4-yl) -2- (4-methoxyphenyl) acetamide
In a10 mL single vial was added 2- (4-methoxyphenyl) -N- (4-methylpiperidin-4-yl) acetamide 2, 2-trifluoroacetate (0.39 g,1.0 mmol), 4- (6-fluoropyridin-3-yl) -6- (prop-2-yn-1-yloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (100 mg,0.34 mmol) and DMSO (2 mL), N, N-diisopropylethylamine (0.3 mL,2 mmol) and the reaction was stirred at 130℃for 3 days. TLC monitoring of the completion of the basic reaction, cooling to room temperature, adding 20mL of ethyl acetate and 10mL of water, separating out the aqueous phase, extracting with ethyl acetate (20 mL. Times.2), washing with saturated brine (15 mL), combining the organic phases, drying the organic phases with anhydrous sodium sulfate, filtering, spin-drying, purifying the residue by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-1/1), collecting 7mg of pale yellow solid, which is the target product (yield) 3.7％).LC-MS(ES-API):m/z＝535.2[M+1]+;1H NMR(400MHz,CDCl3)δ8.35–8.29(m,2H),7.74(d,J＝11.3Hz,1H),7.52(s,1H),7.19(d,J＝8.4Hz,2H),6.99(s,1H),6.90(d,J＝8.4Hz,2H),6.80(d,J＝8.3Hz,1H),5.36–5.32(m,2H),4.08–3.92(m,4H),3.81(s,3H),3.50(s,2H),3.10(s,1H),2.04–1.99(m,4H),1.42(s,3H).
EXAMPLE 26- ((2-hydroxy-2-methylbut-3-yn-1-yl) oxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1-chloro-2-methyl-4- (trimethylsilyl) but-3-yn-2-ol
THF (4 mL) and ethynyl (trimethyl) silane (0.321 mL,2.27 mmol) were added sequentially under nitrogen protection from a 25mL double-necked flask, stirred at 0deg.C for 5min, and n-butyllithium in n-hexane (0.91 mL,2.3mmol,2.5 mol/L) was slowly added and reacted for 30min. Transfer to-78 ℃ and add slowly prepared 1-chloropropan-2-one (0.174 mL,2.16 mmol) in THF solution 6mL, continue the reaction at this temperature for 10min and then raise the temperature to 0 ℃ for 2h. TLC showed that the reaction was completed, quenched by addition of saturated ammonium chloride solution (10 mL), extracted with EA (10 mL. Times.2), and the organic phases were combined and washed with saturated brine (10 mL. Times.2), dried over anhydrous sodium sulfate, and spun-dried. Purifying the residue by silica gel column chromatography (eluent: PE/EA (v/v) =50/1-8/1) to obtain light yellow oily substance 0.25g as target product (yield) 61％).1H NMR(400MHz,CDCl3)δ3.65(d,J＝11.0Hz,1H),3.56(d,J＝11.0Hz,1H),2.74(s,1H),1.54(s,3H),0.15(s,9H).
Step 2 6- ((2-hydroxy-2-methylbut-3-yn-1-yl) oxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
1-Chloro-2-methyl-4- (trimethylsilyl) but-3-yn-2-ol (25 mg,0.13 mmol), K 2CO3 (25 mg,0.18 mmol), 6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 4,20mg,0.044 mmol) and DMAC (2 mL) were sequentially added to a 5mL single-port bottle and reacted under stirring at 85℃for 24h. After TLC detection, the reaction solution is cooled to room temperature, water (10 mL) is added into the reaction solution, EA extraction (15 mL multiplied by 3), saturated saline water is used for washing (10 mL) after the organic phase is combined, anhydrous sodium sulfate is used for drying, filtration and spin-drying are carried out, and the residue is purified by silica gel column chromatography (eluent: DCM/MeOH (v/v) =100/0-100/5), so as to obtain 7mg of light yellow solid which is the target product (yield) 30％).LC-MS(ES-API):m/z＝536.20[M+H]+;1H NMR(400MHz,CDCl3)δ8.42(s,1H),8.23(s,1H),8.21(d,J＝1.9Hz,1H),8.11(s,1H),7.81-7.76(m,1H),7.53(d,J＝8.6Hz,1H),7.09-7.06(m,1H),6.71(dd,J＝14.0,8.6Hz,2H),4.10(d,J＝8.9Hz,1H),4.03(d,J＝8.8Hz,1H),3.92(s,3H),3.91-3.78(m,5H),3.70-3.64(m,2H),3.63(s,2H),2.55(s,1H),2.37-2.31(m,1H),2.22(t,J＝7.6Hz,1H),1.33(s,3H).
EXAMPLE 36- ((2-hydroxybut-3-yn-1-yl) oxy) -4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4- (6-Fluoropyridin-3-yl) -6- (2-hydroxyethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
50ML of a single-port flask was charged with 4- (6-fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,400mg,1.57 mmol), K 2CO3 (440 mg,3.152 mmol), acetonitrile (16 mL) dissolved, 2-bromoethanol (0.15 mL,2.1 mmol) added and placed in an 85℃oil bath under reflux with heating overnight. TLC showed that the reaction was completed, cooled to room temperature, suction-filtered, EA washed (30 mL), the filtrate was spin-dried, and the residue was purified by silica gel column chromatography (eluent: PE/EA (v/v) =2/1-1/4), to give 0.317g of an orange-yellow solid as the target product (yield) 67.5％).LC-MS(ES-API):m/z＝299.05[M+H]+;1H NMR(400MHz,CDCl3)δ8.39(d,J＝2.3Hz,1H),8.25(d,J＝2.0Hz,1H),8.22(s,1H),8.02(td,J＝8.4,2.6Hz,1H),7.21(d,J＝2.1Hz,1H),7.13(dd,J＝8.4,2.5Hz,1H),4.20–4.17(m,2H),4.06(dd,J＝9.2,5.1Hz,2H).
Step 2 4- (6-Fluoropyridin-3-yl) -6- (2-oxoethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 25mL single vial, 4- (6-fluoropyridin-3-yl) -6- (2-hydroxyethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (220 mg,0.738 mmol), naHCO 3 (311 mg,3.68 mmol), dessert-martin-oxidant (407 mg,0.96 mmol) was added, dissolved in DCM (11 mL) and left to stir overnight at room temperature. TLC showed that the reaction was completed, quenched by adding 15mL of saturated sodium thiosulfate solution, extracted with DCM (30 mL. Times.2), washed with 20mL of saturated saline, combined with the organic phase, dried over anhydrous sodium sulfate, filtered, the filtrate was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent PE/EA (v/v) =4/1-1/3) to give 0.162g of an off-white solid as the target product (yield) 74.1％).LC-MS(ES-API):m/z＝296.00[M+H]+;1H NMR(400MHz,CDCl3)δ9.88(s,1H),8.40(d,J＝2.0Hz,1H),8.24(s,1H),8.18(d,J＝2.0Hz,1H),8.05–8.00(m,1H),7.27(s,1H),7.14(dd,J＝8.4,2.9Hz,1H),4.73(s,2H).
Step 3 4- (6-Fluoropyridin-3-yl) -6- (2-hydroxy-4- (trimethylsilyl) but-3-yn-1-yl-oxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
A50 mL double-necked flask was evacuated under nitrogen protection, 8mL of THF and ethynyl (trimethyl) silane (0.143 mL,1.01 mmol) were added, the flask was placed in a low temperature bath at-78 ℃ and stirred for 5min, a hexane solution of n-butyllithium (0.40 mL,1.0mmol,2.5 mol/L) was slowly added and reacted for 30min, then a THF solution of 4- (6-fluoropyridin-3-yl) -6- (2-oxoethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (200 mg,0.67 mmol) was added 13mL and the reaction was continued at 0 ℃ for 10min after the addition. TLC showed that the reaction was quenched by addition of saturated ammonium chloride solution (15 mL), extracted with EA (40 mL. Times.2), the organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was dried. The residue was purified by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-1/2) to give 28mg (yield 11%) of an off-white solid as the target product .LC-MS(ES-API):m/z＝395.10[M+H]+;1H NMR(400MHz,CDCl3)δ8.39(d,J＝2.4Hz,1H),8.30(d,J＝2.1Hz,1H),8.23(s,1H),8.01(td,J＝8.4,2.6Hz,1H),7.24(d,J＝2.1Hz,1H),7.13(dd,J＝8.3,2.7Hz,1H),4.83(dd,J＝6.9,3.4Hz,1H),4.22(dd,J＝9.7,3.5Hz,1H),4.15(dd,J＝9.8,7.2Hz,1H),0.19(s,9H).
Step 4 6- ((2-hydroxybut-3-yn-1-yl) oxy) -4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 5mL single port flask, 4- (6-fluoropyridin-3-yl) -6- (2-hydroxy-4- (trimethylsilyl) but-3-yn-1-yl-oxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (13 mg,0.033 mmol), 5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride (intermediate 3,11mg,0.051 mmol) were added sequentially, dissolved in DMSO (1 mL), K 2CO3 (12 mg,0.087 mmol) and DMAP (1 mg,0.008 mmol) were added and placed in an oil bath for heating reaction at 90℃overnight. TLC showed that the reaction was completed, the reaction solution was cooled to room temperature, washed with 15mL of water, extracted with EA (30 mL. Times.2), and the organic phase was washed with 15mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin-drying. Purification by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=25/1)) gave 12mg (75% yield) of the yellow solid as the target product .LC-MS(ES-API):m/z＝483.10[M+H]+;1H NMR(400MHz,DMSO-d6)δ8.74(s,1H),8.58(s,1H),8.32(s,1H),7.81(dd,J＝11.3,5.7Hz,2H),7.40(dd,J＝8.9,2.8Hz,1H),7.30(s,1H),6.81(d,J＝9.0Hz,1H),6.57(d,J＝8.5Hz,1H),5.90(d,J＝5.8Hz,1H),5.25–5.16(m,1H),4.62(d,J＝5.6Hz,1H),4.49(dd,J＝9.1,6.7Hz,2H),4.22–4.10(m,2H),3.98(dd,J＝9.2,3.6Hz,2H),3.81(s,3H),3.44(d,J＝1.6Hz,1H).
EXAMPLE 4 6- ((2-hydroxy-2-methylbut-3-yn-1-yl) oxy) -4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4- (6-fluoropyridin-3-yl) -6- (2-oxopropoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 50mL single-necked flask, 4- (6-fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile (1000 mg,3.934 mmol), K 2CO3 (1100 mg,7.88 mmol), dissolved in acetonitrile (20 mL), and 1-chloropropane-2-one (0.38 mL,4.7 mmol) were added and the mixture was heated in an 85℃oil bath overnight for reflux reaction. TLC showed that the reaction was completed, cooled to room temperature, suction-filtered, washed with EA (20 mL. Times.3), dried by spin-on-organic phase, and the residue purified by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-1/5) to give 0.801g of a yellowish white solid, which was the target product (yield 66%). LC-MS (ES-API): m/z=311.10 [ m+h ] +.
Step 2 4- (6-Fluoropyridin-3-yl) -6- (2-hydroxy-2-methyl-4- (trimethylsilyl) but-3-yn-1-yl) oxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
100ML double-necked flask was evacuated under nitrogen protection, 20mL of THF and ethynyl (trimethyl) silane (0.348 mL,2.42 mmol) were added, the flask was placed in a low temperature bath at-78 ℃ and stirred for 5min, n-butyllithium n-hexane solution (0.97 mL,2.4mmol,2.5 mol/L) was slowly added, after 30min of reaction, 6-pyruvyloxy-4- (6-fluoro-3-pyridinyl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (500 mg,1.611 mmol) in THF solution 30mL was added, and after 10min of addition, the reaction was continued at 0 ℃ for 2h. TLC showed that the reaction was completed, quenched by addition of 15mL of saturated ammonium chloride solution, extracted with EA (50 mL. Times.2), washed with 30mL of saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was dried by spin, and the residue was purified by silica gel column chromatography (eluent: PE/EA (v/v) =6/1-1/2) to give 0.152g of an off-white solid as the target product (yield 23.1%). LC-MS (ES-API) m/z=409.10 [ m+h ] +.
Step 36- (2-hydroxy-2-methyl-but-3-ynyloxy) -4- [6- [3- [ (6-methoxy-3-pyridinyl) oxy ] azetidin-1-yl ] -3-pyridinyl ] pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 5mL single port flask, 4- (6-fluoropyridin-3-yl) -6- (2-hydroxy-2-methyl-4- (trimethylsilyl) but-3-yn-1-yl) oxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (30 mg,0.073 mmol), 5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride (intermediate 3,24mg,0.111 mmol) were added sequentially, dissolved in DMSO (1 mL), K 2CO3 (23 mg,0.17 mmol), DMAP (1.2 mg,0.01 mmol) were added and placed in an oil bath to react overnight under heating at 90 ℃. TLC showed that the reaction was completed, the reaction solution was cooled to room temperature, washed with 15mL of water, extracted with EA (30 mL. Times.2), and the organic phase was washed with 15mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin-drying. Purification by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=15/1)) afforded 20mg (yield 50%) of the title product as an off-white solid .LC-MS(ES-API):m/z＝497.10[M+H]+;1H NMR(400MHz,CDCl3)δ8.31(d,J＝1.7Hz,1H),8.20(d,J＝2.0Hz,2H),7.70(dd,J＝7.3,2.3Hz,2H),7.19(dd,2H),6.72(d,J＝8.9Hz,1H),6.45(d,J＝8.6Hz,1H),5.12–5.04(m,1H),4.50(dd,J＝8.7,6.7Hz,2H),4.18(dd,J＝9.2,3.8Hz,2H),4.05(dd,J＝30.3,8.9Hz,2H),3.90(s,3H),2.88(s,1H),2.54(s,1H),1.65(s,3H).
EXAMPLE 5 4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) -6- (prop-2-yn-1-yloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4- (6-Fluoropyridin-3-yl) -6- (propan-2-yl-1-yloxy) -pyrazolo [1,5-a ] pyridine-3-carbonitrile
25ML of 1-fluoropyridin-3-yl) -6-hydroxypyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,500mg,1.967 mmol), K 2CO3 (8235 mg,5.91 mmol), was added to a single-port flask, dissolved in DMAC (5 mL), 3-bromoprop-1-yne (0.25 mL) was added, and the mixture was heated in an oil bath at 85℃overnight. TLC showed that the reaction was completed, quenched with 30mL of water, extracted with EA (60 mL. Times.2), the organic phases were combined and washed with 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-1/5) to give 0.315g (yield 55%) of a yellow solid as the target product. LC-MS (ES-API): m/z=293.05 [ m+h ] +.
Step 2 4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) -6- (prop-2-yn-1-yloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 5mL single port flask, 4- (6-fluoropyridin-3-yl) -6- (propan-2-yl-1 yloxy) -pyrazolo [1,5-a ] pyridine-3-carbonitrile (30 mg,0.103 mmol), 5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride (intermediate 3,34mg,0.16 mmol) were added sequentially, dissolved in DMSO (1 mL), K 2CO3 (32 mg,0.23 mmol) and DMAP (1.2 mg,0.01 mmol) were added and placed in an oil bath to react overnight with heating at 90 ℃. TLC showed the reaction was cooled to room temperature, washed with 15mL of water, extracted with EA (30 ml×2), and the organic phase was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin-drying. Silica gel column chromatography purification (eluent: pure DCM-DCM/MeOH (v/v=20/1)) afforded 25mg (yield 54%) of the title product as a white solid .LC-MS(ES-API):m/z＝453.20[M+H]+;1H NMR(400MHz,CDCl3)δ8.31(t,2H),8.21(s,1H),7.72–7.68(m,2H),7.18(dd,J＝9.0,2.8Hz,1H),7.13(d,J＝1.5Hz,1H),6.72(d,J＝8.9Hz,1H),6.46(d,J＝8.6Hz,1H),5.12–5.05(m,1H),4.78(d,J＝1.8Hz,2H),4.50(dd,J＝8.5,6.9Hz,2H),4.18(dd,J＝9.2,3.8Hz,2H),3.90(s,3H),2.64(s,1H).
EXAMPLE 6- (but-2-yn-1-yloxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1-2-alkynyl butyl methylsulfonate
In a 10mL single flask, but-2-yn-1-ol (500 mg,7.13 mmol) was added under ice-bath conditions, dissolved in DCM (5 mL), TEA (1.5 mL,11 mmol) was added, methanesulfonyl chloride (0.725 mL,9.27 mmol) was slowly added dropwise, and the mixture was allowed to spontaneously warm to room temperature after the addition. TLC showed that after the reaction was completed, 3mL of water was added to quench the reaction, DCM (15 mL. Times.2) was used for extraction, the organic phase was washed with 8mL of saturated brine, dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated and purified by column chromatography on silica gel (eluent: PE/EA (v/v) =6/1-2/1) to give 0.58g of pale yellow oily substance, yield 55.00%, which was the target product. 1H NMR(400MHz,CDCl3 ) δ4.81 (dd, j=4.7, 2.3hz, 2H), 3.10 (s, 3H), 1.89 (t, j=2.4 hz, 3H).
Step 2 6- (but-2-yn-1-yloxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
10ML of 2-alkynylbutyl methanesulfonate (20 mg,0.14 mmol), K 2CO3 (37 mg,0.27 mmol), 6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 4,30mg,0.07 mmol) was added via a single vial and dissolved in DMF (1.5 mL) and reacted overnight at 60 ℃. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, 15mL of water was added, EA (40 mL. Times.2) was extracted, the organic phase was washed with 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography on silica gel (eluent: pure DCM-DCM/MeOH (v/v=10/1)), to give 15.0mg of a pale yellow solid, yield 45.00%, as the target product .LC-MS(ES-API):m/z＝506.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.40(s,1H),8.30(s,1H),8.23(s,1H),8.11(s,1H),7.78(d,J＝6.8Hz,1H),7.67(s,1H),7.14(s,1H),6.83–6.58(m,2H),4.74(s,2H),3.87(d,J＝39.1Hz,6H),3.60(s,3H),2.92(d,J＝28.8Hz,2H),2.81–2.66(m,1H),1.89(s,3H),1.68–1.64(m,1H).
EXAMPLE 7 6- (but-2-yn-1-yloxy) -4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of 2-alkynylbutyl methylsulfonate (example 6, step 1,21mg,0.14 mmol), K 2CO3 (39 mg,0.28 mmol), 6-hydroxy-4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 5,30mg,0.07 mmol) was added to DMF (1.5 mL) and dissolved for 60℃reaction. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, washed with 15mL of water, extracted with EA (40 mL. Times.2), the organic phase was washed with 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)), to give 20.0mg of a yellow solid, yield 60.00%, as the target product .LC-MS(ES-API):m/z＝479.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.52(d,J＝4.2Hz,1H),8.28(dd,J＝11.1,2.1Hz,2H),8.20(s,1H),7.71–7.62(m,2H),7.22–7.16(m,1H),7.12(dd,J＝8.4,5.0Hz,2H),6.77(d,J＝8.9Hz,1H),4.72(d,J＝2.2Hz,2H),4.09(d,J＝13.0Hz,2H),3.53–3.42(m,2H),2.94(s,2H),1.88(s,3H),1.65(d,J＝3.9Hz,4H).
EXAMPLE 8 6- ((2-hydroxy-2-methylbut-3-yn-1-yl) oxy) -4- (6- (3- (4-methoxyphenoxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4- (6-fluoropyridin-3-yl) -6- (2-oxopropoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
50ML of single port flask was added 4- (6-fluoropyridin-3-yl) -6-hydroxy-pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,1000mg,3.93 mmol), K 2CO3 (1100 mg,7.88 mmol), acetonitrile (20 mL) was added to dissolve it, and 1-chloropropane-2-one (0.38 mL,4.7 mmol) was added and the reaction was refluxed overnight at 85 ℃. After the TLC shows that the reaction solution is cooled to room temperature, the filter cake is washed by EA (50 mL) for multiple times, the organic phase is washed by saturated saline water (20 mL), dried by anhydrous sodium sulfate and filtered, and the filtrate is concentrated and purified by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-1/5), so that 0.80g of yellow-white solid is obtained, and the yield is 65.66%, namely the target product. LC-MS (ES-API): m/z=311.1 [ m+h ] +.
Step 2 4- (6-Fluoropyridin-3-yl) -6- (2-hydroxy-2-methyl-4-trimethylsilyl-but-3-ynyloxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
After 100mL of a double-necked flask was evacuated under nitrogen atmosphere, anhydrous THF (20 mL) and ethynyl (trimethyl) silane (0.348 mL,2.42 mmol) were added, the flask was placed in a-78 ℃ low temperature tank, n-butyllithium in n-hexane solution (0.97 mL,2.4mmol,2.5 mol/L) was slowly added, and after 30min of reaction, 6-pyruvyloxy-4- (6-fluoro-3-pyridinyl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (500 mg,1.611 mmol) dissolved in THF (30 mL) was added, and the reaction was continued at 0 ℃ for 2h after 5-10 min. After completion of the reaction, TLC showed that 15mL of saturated ammonium chloride solution was added to quench the reaction, EA (50 mL. Times.2) was extracted, and the organic phase was washed with 30mL of saturated brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by column chromatography on silica gel (eluent: PE/EA (v/v) =6/1-1/2) to give 0.152g of an off-white solid, 23.10% yield, which was the target product. LC-MS (ES-API): m/z=409.1 [ m+h ] +.
Step 3 6- ((2-hydroxy-2-methylbut-3-yn-1-yl) oxy) -4- (6- (3- (4-methoxyphenoxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 5mL single vial was added 4- (6-fluoro-3-pyridinyl) -6- (2-hydroxy-2-methyl-4-trimethylsilyl-but-3-ethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (25 mg,0.061 mmol), 3- (4-methoxyphenoxy) azetidine hydrochloride (50 mg,0.23 mmol), potassium carbonate (50 mg,0.36 mmol), 4-dimethylaminopyridine (2 mg,0.016 mmol), DMSO (1 mL), and reacted at 90℃in an oil bath. After TLC detection of the reaction of the starting materials, the reaction solution was cooled to room temperature, 15mL of water was added, EA (40 mL. Times.2) was extracted, the organic phase was washed with water (10 mL. Times.4), saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: DCM/MeOH (v/v) =80/1-50/1) to give 20mg of a white solid as the target product (yield) 30.32％).LC-MS(ES-API):m/z＝496.1[M+H]+;1H NMR(400MHz,DMSO-d6)δ8.73(d,J＝1.9Hz,1H),8.58(s,1H),8.32(d,J＝1.8Hz,1H),7.79(dd,J＝8.6,2.4Hz,1H),7.31(d,J＝1.9Hz,1H),6.89-6.86(m,3H),6.78(d,J＝9.1Hz,1H),6.57(d,J＝8.6Hz,1H),5.17-5.10(m,1H),4.47(dd,J＝9.4,6.6Hz,2H),4.06(s,2H),3.95(dd,J＝9.4,3.6Hz,2H),3.71(s,3H),3.38(s,1H),1.47(s,3H).
EXAMPLE 9 4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) -6- (2- (prop-2-yn-1-yloxy) ethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4- (6-Fluoropyridin-3-yl) -6- (2-hydroxyethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
50ML of a single-port flask was charged with 4- (6-fluoropyridin-3-yl) -6-hydroxy-pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,500mg,1.97 mmol), K 2CO3 (550 mg,3.94 mmol), acetonitrile (15 mL) was dissolved, and 2-bromoethanol (0.167 mL,2.36 mmol) was added and the reaction was refluxed overnight at 85 ℃. After the TLC shows that the reaction liquid is cooled to room temperature, suction filtration is carried out, an EA (30 mL) is used for washing a filter cake, and the filtrate is concentrated and purified by silica gel column chromatography (eluent: PE/EA (v/v) =2/1-1/4), so as to obtain 0.40g of orange yellow solid, and the yield is 67.70%, namely the target product. LC-MS (ES-API): m/z=299.1 [ m+h ] +.
Step 2 4- (6-Fluoropyridin-3-yl) -6- (2- (prop-2-yn-1-yloxy) ethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 25mL single vial was added 4- (6-fluoropyridin-3-yl) -6- (2-hydroxyethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (130 mg,0.44 mmol), anhydrous THF (6.5 mL), naH (21 mg,0.53 mmol) at 0deg.C, and after 30min of reaction 3-bromopropyne (0.05 mL,0.52 mmol) was added dropwise and the reaction was warmed to room temperature after addition and stirred overnight. TLC showed that after the reaction was completed, the reaction solution was washed with water (15 mL), EA (60 mL. Times.2) was extracted, the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: PE/EA (v/v) =6/1-1/4) to give 20.0mg of a white solid, yield 31.00%, which was the target product .LC-MS(ES-API):m/z＝337.15[M+H]+;1H NMR(400MHz,CDCl3)δ8.38(d,J＝2.0Hz,1H),8.25(d,J＝1.9Hz,1H),8.22(s,1H),8.04–7.98(m,1H),7.23(d,J＝2.0Hz,1H),7.13(dd,J＝8.4,2.7Hz,1H),4.28(d,J＝2.3Hz,2H),4.26–4.22(m,2H),3.98–3.95(m,2H),2.49(t,J＝2.3Hz,1H).
Step 3 4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) -6- (2- (prop-2-yn-1-yloxy) ethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
In a 5mL single port flask, 4- (6-fluoropyridin-3-yl) -6- (2- (prop-2-yn-1-yloxy) ethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (20 mg,0.06 mmol), 5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride (intermediate 3,19mg,0.09 mmol) were added sequentially, dissolved in DMSO (1 mL), K 2CO3 (19 mg,0.14 mmol), DMAP (1.0 mg,0.01 mmol) was added and the reaction was heated at 90℃overnight. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, washed with 15mL of water, extracted with EA (30 mL. Times.2), and the organic phase was washed with 15mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=20/1)), to give 12.0mg of a white solid, yield 41.00%, as the target product .LC-MS(ES-API):m/z＝497.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.30(d,J＝1.6Hz,1H),8.19(s,1H),8.16(d,J＝1.7Hz,1H),7.70(d,J＝6.1Hz,2H),7.53(dd,J＝5.6,3.2Hz,1H),7.15(d,J＝1.9Hz,1H),6.72(d,J＝8.9Hz,1H),6.45(d,J＝8.6Hz,1H),5.12–5.04(m,1H),4.53–4.46(m,2H),4.28(d,J＝2.3Hz,2H),4.23–4.16(m,4H),4.00–3.94(m,2H),3.90(s,3H),2.49(s,1H).
EXAMPLE 10 6- (but-2-yn-1-yloxy) -4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of 2-alkynylbutyl methanesulfonate (20 mg,0.14 mmol), K 2CO3 (36 mg,0.26 mmol), 6-hydroxy-4- (6- (6- (6-methoxynicotinyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (30 mg,0.07 mmol) were added to the flask and dissolved in DMF (1.5 mL) and reacted at 60 ℃. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, 15mL of water was added, EA (40 mL. Times.2) was extracted, the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH ((v/v=10/1)) to give 15.0mg of a pale yellow solid, yield 45.00%, as the target product .LC-MS(ES-API):m/z＝520.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.50(d,J＝1.5Hz,1H),8.30(dd,J＝12.8,1.7Hz,2H),8.21(s,1H),7.89(dd,J＝8.5,2.1Hz,1H),7.74(dd,J＝8.8,2.2Hz,1H),7.11(d,J＝1.7Hz,1H),6.77(d,J＝8.7Hz,1H),6.63(d,J＝8.9Hz,1H),4.78–4.69(m,4H),4.38–4.24(m,1H),3.98(s,3H),3.84–3.65(m,3H),2.93(dd,J＝14.1,7.0Hz,1H),2.38–2.18(m,1H),1.88(s,3H).
EXAMPLE 11 6- (but-3-yn-1-yloxy) -4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1-3-alkynyl-butyl methylsulfonate
In a 25mL single-necked flask under ice-bath condition, but-3-yn-1-ol (1000 mg,14.27 mmol) was added, DCM (10 mL) was dissolved, TEA (3 mL,21.4 mmol) was added, methanesulfonyl chloride (1.45 mL,18.5 mmol) was slowly added dropwise, and the mixture was allowed to spontaneously warm to room temperature after the addition. TLC showed that after the reaction was completed, the reaction was quenched by adding 8mL of water, extracted with DCM (20 mL. Times.2), the organic phase was washed with 15mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: PE/EA (v/v) =10/1-2/1) to give 2.02g of pale yellow oil, yield 95.50%, which was the target product .1H NMR(400MHz,CDCl3)δ4.30(t,J＝6.7Hz,2H),3.05(s,3H),2.65(td,J＝6.7,2.6Hz,2H),2.06(t,J＝2.6Hz,1H).
Step 2 6- (but-3-yn-1-yloxy) -4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of 3-alkynylbutyl methanesulfonate (21 mg,0.14 mmol), K 2CO3 (39 mg,0.28 mmol), 6-hydroxy-4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 5,30mg,0.07 mmol) were added to a single vial and dissolved in DMF (1.5 mL) and reacted at 60 ℃. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, 15mL of water was added, EA (40 mL. Times.2) was extracted, the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)), to give 10.0mg of a yellow solid, yield 30.00%, as the target product .LC-MS(ES-API):m/z＝479.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.52(d,J＝4.4Hz,1H),8.30(d,J＝2.3Hz,1H),8.20(s,1H),8.13(d,J＝2.0Hz,1H),7.70–7.62(m,2H),7.22–7.18(m,1H),7.14(s,1H),7.12(d,J＝2.1Hz,1H),6.77(d,J＝8.9Hz,1H),4.15(t,J＝6.7Hz,2H),4.12–4.04(m,2H),3.54–3.44(m,2H),2.94(s,2H),2.79–2.72(m,2H),2.08(t,J＝2.6Hz,1H),1.66–1.64(m,4H).
EXAMPLE 12 6- (but-3-yn-1-yloxy) -4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of 3-alkynylbutyl methanesulfonate (example 11, step 1,20mg,0.13 mmol), K 2CO3 (36 mg,0.27 mmol), 6-hydroxy-4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 6,30mg,0.06 mmol) was added to dissolve it and reacted at 60℃with DMF (1.5 mL). TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, water (15 mL), EA (40 mL. Times.2) was added, the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)), to give 10.0mg of a yellow solid, yield 30.00%, as the target product .LC-MS(ES-API):m/z＝520.1[M+H]+;1H NMR(400MHz,CDCl3)δ8.49(d,J＝1.8Hz,1H),8.32(d,J＝2.0Hz,1H),8.20(s,1H),8.14(d,J＝1.8Hz,1H),7.88(dd,J＝8.7,2.2Hz,1H),7.73(dd,J＝8.8,2.3Hz,1H),7.11(d,J＝1.8Hz,1H),6.77(d,J＝8.6Hz,1H),6.63(d,J＝8.9Hz,1H),5.29(s,2H),4.75(d,J＝5.9Hz,2H),4.14(t,J＝6.7Hz,2H),3.97(s,3H),3.79–3.69(m,2H),2.79–2.74(m,2H),2.37–2.18(m,1H),2.08(t,J＝2.4Hz,1H),2.06–1.97(m,1H).
EXAMPLE 13 6- (but-3-yn-1-yloxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of single port flask were charged with methylsulfonic acid-3-alkynylbutyl ester (example 11 step 1,20mg,0.14 mmol), K 2CO3 (37 mg,0.27 mmol), 6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 4,30mg,0.07 mmol), dissolved in DMF (1.5 mL) and reacted at 60℃overnight. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, 15mL of water was added, EA (40 mL. Times.2) was extracted, the organic phase was washed with 20mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography on silica gel (eluent: pure DCM-DCM/MeOH (v/v=10:1)), to give 12.0mg of a pale yellow solid, yield 36.00%, as the target product .LC-MS(ES-API):m/z＝506.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.40(d,J＝1.7Hz,1H),8.22(s,1H),8.15(d,J＝1.5Hz,1H),8.10(s,1H),7.78(dd,J＝8.6,2.1Hz,1H),7.64(d,J＝7.8Hz,1H),7.15(d,J＝1.5Hz,1H),6.70(dd,J＝12.9,8.7Hz,2H),4.16(t,J＝6.7Hz,2H),3.92(s,3H),3.84(d,J＝9.9Hz,2H),3.78(d,J＝4.7Hz,2H),3.59(s,4H),2.77(dd,J＝6.5,4.1Hz,2H),2.73–2.66(m,1H),2.09(s,1H),2.05–1.95(m,1H).
EXAMPLE 14 6- ((4-hydroxy-4-methylpent-2-yn-1-yl) oxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4-methylpent-2-yn-1, 4-diol
After evacuating under nitrogen protection of a 100mL double-necked flask, a tetrahydrofuran solution (1.0 mol/L,36mL,36 mmol) of ethyl magnesium bromide was added, and at 0℃in a low-temperature vessel, prop-2-yn-1-ol (1000 mg,17.84 mmol) dissolved in THF (10 mL) was added and reacted at room temperature after the addition was completed. After 3h acetone (1.24 g,21.40 mmol) in THF (10 mL) was added and the reaction continued at room temperature overnight. TLC showed that after the reaction was completed, the reaction was quenched by dropwise addition of saturated ammonium chloride solution (20 mL), extracted with EA (60 mL. Times.2), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: PE/EA (v/v) =4/1-1/2) to give 1.15g of pale yellow oily substance in a yield of 56.29%, which was the target product. 1H NMR(400MHz,CDCl3 ) δ4.26 (s, 2H), 3.46 (s, 2H), 1.50 (s, 6H).
Step 2 4-hydroxy-4-methyl-pent-2-yn-1-ylmethylsulfonate
To a 10mL single-necked flask under ice-bath conditions was added 4-methylpent-2-yne-1, 4-diol (500 mg,4.38 mmol), DCM (5 mL) was added for dissolution, triethylamine (0.93 mL,6.6mmol, content 99.0%) was added, methanesulfonyl chloride (0.45 mL,5.8 mmol) was slowly added dropwise, and the mixture was allowed to spontaneously warm to room temperature for reaction for 1.5h after the addition was completed. TLC showed that after the reaction was quenched by addition of 8mL of water, extracted with DCM (20 mL. Times.2), the organic phase was washed with 15mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography on silica gel (eluent: PE/EA (v/v) =4/1-1/2) to give 0.43g of a reddish brown oil in 50.9% yield as the target product. 1H NMR(400MHz,CDCl3 ) δ4.86 (s, 2H), 3.12 (s, 3H), 1.52 (s, 6H).
Step 3 6- ((4-hydroxy-4-methylpent-2-yn-1-yl) oxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of single port flask was added 4-hydroxy-4-methyl-pent-2-yn-1-ylmethylsulfonate (26 mg,0.14 mmol), K 2CO3 (37 mg,0.27 mmol), 6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 4,30mg,0.07 mmol), dissolved in DMF (1.5 mL) and reacted at 80℃overnight. After TLC showed that the reaction solution was cooled to room temperature, washed with 10mL of water, extracted with EA (40 mL. Times.2), and the organic phase was washed with 20mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography on silica gel (eluent: pure DCM-DCM: meOH (v/v=10:1)), to give 15.0mg of a pale yellow solid, yield 41.00%, as the target product .LC-MS(ES-API):m/z＝550.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.40(d,J＝2.1Hz,1H),8.29(d,J＝1.9Hz,1H),8.23(s,1H),8.11(s,1H),7.79(dd,J＝8.7,2.4Hz,1H),7.66(d,J＝7.0Hz,1H),7.14(d,J＝1.9Hz,1H),6.70(dd,J＝12.0,8.8Hz,2H),4.79(s,2H),3.92(s,3H),3.88–3.79(m,4H),3.65–3.56(m,4H),2.73(s,1H),2.37–2.18(m,1H),2.07–1.97(m,1H),1.53(s,6H).
EXAMPLE 15 4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) -6- ((4-hydroxy-4-methylpent-2-yn-1-yl) oxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of 4-hydroxy-4-methyl-pent-2-yn-1-ylmethylsulfonate (example 14 step 2,27mg,0.14 mmol), K 2CO3 (39 mg,0.28 mmol), 6-hydroxy-4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 5,30mg,0.07 mmol) was added to dissolve in DMF (1.5 mL, content 100%) and reacted overnight at 80 ℃. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, washed with 10mL of water, extracted with EA (40 mL. Times.2), the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)), to give 27.0mg of a yellow solid, yield 73.00%, as the target product .LC-MS(ES-API):m/z＝523.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.51(d,J＝3.2Hz,1H),8.30(d,J＝1.8Hz,1H),8.26(d,J＝1.5Hz,1H),8.20(s,1H),7.70–7.61(m,2H),7.22–7.16(m,1H),7.12(d,J＝11.6Hz,2H),6.77(d,J＝8.8Hz,1H),4.77(s,2H),4.09(d,J＝13.0Hz,2H),3.53–3.42(m,2H),2.94(s,2H),1.67–1.62(m,4H),1.52(s,6H).
EXAMPLE 16- ((4-hydroxy-4-methylpent-2-yn-1-yl) oxy) -4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of 4-hydroxy-4-methyl-pent-2-yn-1-ylmethylsulfonate (example 14, step 2,25mg,0.13 mmol), K 2CO3 (36 mg,0.26 mmol), 6-hydroxy-4- (6- (6- (6-methoxynicotinoyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 6,30mg,0.06 mmol) was added to dissolve it and reacted at 80℃overnight. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, washed with water (10 mL), extracted with EA (40 mL. Times.2), the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)) to give 15.0mg of a white solid, yield 41.00%, as the target product .LC-MS(ES-API):m/z＝564.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.50(s,1H),8.33(d,J＝1.2Hz,1H),8.28(d,J＝1.2Hz,1H),8.21(s,1H),7.89(d,J＝6.5Hz,1H),7.74(d,J＝8.4Hz,1H),7.11(s,1H),6.77(d,J＝8.6Hz,1H),6.64(d,J＝8.5Hz,1H),4.78(s,2H),4.76(d,J＝5.8Hz,2H),4.32(s,1H),3.98(s,3H),3.84–3.67(m,3H),2.93(dd,J＝12.9,5.5Hz,1H),2.26–2.08(m,1H),2.06–1.91(m,1H),1.53(s,6H).
EXAMPLE 17 6- ((4-hydroxy-4-methylpent-2-yn-1-yl) oxy) -4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 4- (6-Fluoropyridin-3-yl) -6- (2-hydroxyethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile
10ML of single port flask was charged with 4-hydroxy-4-methyl-pent-2-yn-1-ylmethylsulfonate (example 14 step 2,303mg,1.58 mmol), K 2CO3 (439 mg,3.14 mmol), 4- (6-fluoropyridin-3-yl) -6-hydroxy-pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 1,200mg,0.79 mmol), dissolved in DMF (6 mL) and reacted at 80℃overnight. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, washed with water (20 mL), extracted with EA (70 mL. Times.2), the organic phase was washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: PE/EA (v/v) =2/1-1/2), to give 0.24g of a yellow solid, which was the target product .LC-MS(ES-API):m/z＝351.1[M+H]+;1H NMR(400MHz,DMSO-d6)δ8.79(d,J＝2.0Hz,1H),8.64(s,1H),8.50(d,J＝2.2Hz,1H),8.30–8.23(m,1H),7.54(d,J＝2.0Hz,1H),7.39(dd,J＝8.4,2.4Hz,1H),4.98(s,2H),1.36(s,6H).
Step 2 6- ((4-hydroxy-4-methylpent-2-yn-1-yl) oxy) -4- (6- (3- ((6-methoxypyridin-3-yl) oxy) azetidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 5mL single vial was added 4- (6-fluoropyridin-3-yl) -6- (2-hydroxyethoxy) pyrazolo [1,5-a ] pyridine-3-carbonitrile (30 mg,0.09 mmol), 5- (azetidin-3-yloxy) -2-methoxypyridine hydrochloride (intermediate 3,28mg,0.13 mmol), DMSO (1 mL) was added to dissolve, K 2CO3 (27 mg,0.20 mmol), DMAP (1.0 mg,0.01 mmol) was added and reacted overnight at 90 ℃. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, washed with 15mL of water, extracted with EA (30 mL. Times.2), the organic phase was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)), to give 30.0mg of a white solid, yield 70.00%, as the target product .LC-MS(ES-API):m/z＝511.1[M+H]+;1H NMR(400MHz,CDCl3)δ8.29(d,J＝13.0Hz,2H),8.21(s,1H),7.70(dd,J＝11.6,2.5Hz,2H),7.18(dd,J＝8.9,2.9Hz,1H),7.12(s,1H),6.72(d,J＝8.9Hz,1H),6.46(d,J＝8.7Hz,1H),5.12–5.04(m,1H),4.78(s,2H),4.50(dd,J＝8.5,6.7Hz,2H),4.18(dd,J＝9.0,3.8Hz,2H),3.90(s,3H),1.52(s,6H).
EXAMPLE 18- ((3-cyclopropylprop-2-yn-1-yl) oxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1 3-cyclopropyl-2-yn-1-ylmethane sulfonate
3-Cyclopropyl-2-yn-1-ol (1000 mg,10.40 mmol) was added to a10 mL single-necked flask under ice-bath condition, dissolved in DCM (10 mL), and triethylamine (2.92 mL,20.8 mmol) was added thereto, followed by slowly dropwise addition of methanesulfonyl chloride (1.06 mL,13.6 mmol), and the mixture was allowed to spontaneously warm to room temperature for 1h after the completion of the addition. TLC showed that after the reaction was completed, the reaction was concentrated under reduced pressure, the concentrated solution was extracted with EA (15 mL. Times.2), washed with saturated sodium bicarbonate solution (8 mL. Times.2), dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated to give 0.33g of brown oil, yield 18.00%, as the target product .1H NMR(400MHz,CDCl3)δ4.81(d,J＝2.1Hz,2H),3.10(s,3H),1.30–1.27(m,1H),0.85–0.74(m,4H).
Step 3 6- ((3-Cycloprop-2-yn-1-yl) oxy) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of single port flask was added 3-cyclopropylprop-2-yn-1-ylmethylsulfonate (23 mg,0.13 mmol), K 2CO3 (37 mg,0.27 mmol), 6-hydroxy-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 4,30mg,0.07 mmol) was dissolved by adding DMF (1.5 mL) and the reaction was stirred at 65℃overnight. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, 10mL of water was added, EA (40 mL. Times.2) was extracted, the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)) to give 18.0mg of a pale yellow solid, yield 51.00%, as the target product .LC-MS(ES-API):m/z＝532.2[M+H]+;1H NMR(400MHz,CDCl3)δ8.42–8.38(m,1H),8.28(d,J＝1.8Hz,1H),8.23(s,1H),8.11(s,1H),7.78(dd,J＝8.7,2.4Hz,1H),7.65(d,J＝7.5Hz,1H),7.13(d,J＝1.8Hz,1H),6.70(dd,J＝11.8,8.8Hz,2H),4.73(d,J＝1.5Hz,2H),3.92(s,3H),3.88–3.77(m,4H),3.66–3.56(m,4H),2.76–2.67(m,1H),2.26–1.93(m,1H),1.38–1.35(m,1H),0.82–0.78(m,2H),0.75–0.70(m,2H).
EXAMPLE 19 6- ((3-Cycloprop-2-yn-1-yl) oxy) -4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
5ML of single port flask was charged with 3-cyclopropylprop-2-yn-1-ylmethylsulfonate (example 18 step 1,25mg,0.14 mmol), K 2CO3 (39 mg,0.28 mmol), 6-hydroxy-4- (6- (4-hydroxy-4- (pyridin-2-ylmethyl) piperidin-1-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (intermediate 5,30mg,0.07 mmol), DMF (1.5 mL) was added to dissolve and the reaction was carried out overnight at 65 ℃. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature, water (10 mL), EA (40 mL. Times.2) was added, the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (eluent: pure DCM-DCM/MeOH (v/v=10/1)) to give 25.0mg of a yellow solid, yield 70.00%, as the target product .LC-MS(ES-API):m/z＝505.3[M+H]+;1H NMR(400MHz,CDCl3)δ8.55–8.49(m,1H),8.30(d,J＝2.1Hz,1H),8.25(d,J＝1.8Hz,1H),8.20(s,1H),7.73–7.62(m,2H),7.23–7.17(m,1H),7.13(d,J＝7.7Hz,1H),7.10(d,J＝1.7Hz,1H),6.77(d,J＝8.9Hz,1H),4.71(s,2H),4.16–4.03(m,2H),3.55–3.44(m,2H),2.94(s,2H),1.65(d,J＝3.6Hz,4H),1.38–1.32(m,1H),0.82–0.76(m,2H),0.75–0.68(m,2H).
Biological Activity test examples:
Test example 1 test of the Compounds of the invention for Ret wt, RET CCDC-6, ret M918T, ret V804L, ret V804M kinase inhibitory Activity
1. The purpose of the experiment is as follows:
The inhibitory activity of the series of compounds against 6 kinases, ret wt, ret CCDC-6, ret M918T, ret V804L, ret V804M, was tested by HTRF method and IC 50 values were determined.
2. The experimental reagents and consumables used were as follows:
1)HTRF KinEASE-TK kit(Cisbio,62TK0PEC)
2)Ret wt(Invitrogen,PV3082)
3)Ret V804M(Signalchem,R02-12GG-10)
4)MgCl2(Sigma,M1028)
5)ATP(Promega,V910B)
6)DTT(Invitrogen,P2325)
7)DMSO(Sigma,D8418)
8)384-well plate,white,low volume,round-bottom(Greiner,784075)
9)384-Well Polypropylene microplate,Clear,Flatt Bottom,Bar Code(Labcyte,P-05525-BC)
10)96-well polypropylene plate(Nunc,249944)
11)Plate shaker(Thermo,4625-1CECN/THZ Q)
12)Centrifuge(Eppendorf,5810R)
13)Envision 2104multi-label Reader(PerkinElmer,2104-10-1)
14)Echo(Labcyte,550)
3. Experimental procedure
3.1 Preparation of 1x kinase reaction buffer:
1 volume of 5 Xkinase reaction buffer and 4 volumes of water, 5mM MgCl 2;1mM DTT;1mM MnCl2.
3.2 Transfer of 10nL of diluted compound per well with an Echo 550 reaction plate (784075, greiner);
3.3 the reaction plate was sealed with a sealing plate membrane and centrifuged at 1000g for 1 min.
3.4 Preparation of 2x kinase with 1x kinase reaction buffer.
3.5 Mu.L kinase (formulated in step 3.4) was added to each well in the reaction plate. 1000g of the reaction plate is sealed by a sealing plate film and centrifuged for 30 seconds, and the reaction plate is placed at room temperature
10 Minutes.
3.6 Preparation of 4 XTK-substrate-biotin and 4 XATP with 1 Xkinase reaction buffer, mixing well, and adding 5. Mu.LK-substrate-biotin/ATP mixture to the reaction plate.
3.7 Sealing the reaction plate with a sealing plate membrane, centrifuging 1000g for 30 seconds, and reacting for 40 minutes at room temperature.
3.8 4 XSa-XL 665 (250 nM) was formulated in HTRF detection buffer.
3.9 Mu.l of Sa-XL 665 and 5. Mu.l of TK-anti-Cryptate were added per well and centrifuged at 1000g for 30 seconds and reacted at room temperature for 1 hour.
3.10 Fluorescence signals at 615nm (Cryptate) and 665nm (XL 665) were read with Envision 2104.
4. Data analysis
4.1 Calculating the Ratio per well (ratio_665/615 nm)
4.2 Inhibition was calculated as follows:
Average of CEP-32496 reads for all positive control wells
Mean value of DMSO well readings for all negative control wells
Wherein the chemical name of CEP-32496 is N- [3- [ (6, 7-dimethoxy-4-quinazolinyl) oxy ] phenyl ] -N' - [5- (2, 2-trifluoro-1, 1-dimethylethyl) -3-isoxazolyl ] urea.
4.3 Calculation IC 50:
IC 50 (median inhibitory concentration) of the compound was obtained using the following non-linear fit formula and data analysis was performed using Graphpad 6.0 software.
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×Hill Slope))
Log of compound concentration Y, inhibition (% inhibition)
5. The experimental results are shown in table a:
table A kinase inhibitory Activity of the Compounds of the invention
Examples IC50(nM),Ret wt IC50(nM),Ret V804M
Example 1 5.16 -
Example 3 0.22 1.67
Example 4 0.29 0.92
Example 5 5.89 33.54
Example 6 1.91 14.82
Example 7 9.72 51.35
Example 8 0.27 1.37
Example 9 0.46 6.36
Note that "-" in Table A indicates no test.
As shown in Table A, the compounds of the invention have good inhibition effects on Ret wt and Ret V804M kinase, and other compounds of the invention have good inhibition effects on Ret CCDC-6, ret M918T and Ret V804L kinase.
Test example 2 test of the cell proliferation inhibitory Activity of the Compounds of the invention against BAF3-KIF5B-RET-WT cells
1. The purpose of the experiment is as follows:
The compounds were tested for their cell proliferation inhibitory activity in BAF3-KIF5B-RET-WT tumor cells using the CTG method and the median inhibitory concentration (IC 50) was calculated.
2. The experimental reagents and test samples used were as follows:
1)CTG:CellTiter-Glo(Promega)
2) RPMI-1640 medium (Gibco)
3) FBS fetal bovine serum (Gibco)
4)DMSO(Sigma)
5) Double antibody penicillin and streptomycin (HyClone)
6) 96 Well cell culture plate, white wall and impermeable bottom (Corning)
7) BAF3 cells (purchased from Shanghai Mingjin organism)
8) BAF3-KIF5B-RET-WT cell (Steady Transit cell line, constructed by the pharmacology division of the east Guangdong optical pharmaceutical Co., ltd.)
3. The experimental steps are as follows:
1) Cell seeding
Cells in exponential growth phase, BAF3 and BAF3-KIF5B-RET-WT, were collected and viable Cell counted using a Vi-Cell XR cytometer. The cell suspension was adjusted to the corresponding concentration with RPMI-1640 complete medium (89% RPMI-1640+10% FBS+1% diabody). mu.L of cell suspension was added to each well and the cell concentrations of BAF3 and BAF3-KIF5B-RET-WT were 2,000 cells/well and 10,000 cells/well, respectively, in 96-well cell culture plates.
2) Dosing treatment
A working solution was prepared by dissolving each test compound in DMSO to give a final concentration of 10mM stock solution. The stock solution was 100-fold diluted with stock solution and RPMI-1640 complete medium, and then subjected to 3-fold gradient dilution 9 times to obtain 10 working solutions in total, each solution having a DMSO final concentration of 0.1%.
B cell dosing, namely after the cells are incubated overnight, 10 mu.l of working solution with the concentration of 10 are sequentially added, and the cells are placed in a 37 ℃ and 5% CO 2 incubator for incubation for 72 hours, and meanwhile negative control without adding compound is established.
3) Read plate detection
After 72 hours of drug treatment, 50. Mu.l (1/2 of the culture volume) of CTG solution, which had been previously thawed and equilibrated to room temperature, was added to each well according to the CTG protocol, mixed with a microplate shaker for 2 minutes, and after 10 minutes at room temperature, the fluorescence signal value was measured using a multifunctional microplate reader.
4) Data analysis
Cell viability%Vsample/Vvehicle control X100%. Where Vsample is the reading for the drug-treated group and Vvehicle control is the average value for the solvent control group. The non-linear regression model was used to plot the S-type dose-survival curve and calculate IC 50 values using GRAPHPAD PRISM 5.0.0 software and the experimental results are shown in table B.
TABLE B results of experiments on the inhibitory Activity of the inventive Compounds on BAF3-KIF5B-RET-WT cell proliferation
As can be seen from Table B, the compounds of the examples of the present invention also have a good inhibitory effect on the cell proliferation of BAF3-KIF5B-RET-WT cells.
In the description of the present specification, the descriptions of the terms "one embodiment," "some embodiments," "some implementations," "examples," "particular examples," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the features of the different embodiments, implementations or examples and the different embodiments, implementations or examples described in this specification may be combined and combined by persons skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that changes, modifications, substitutions and variations may be made therein by those of ordinary skill in the art without departing from the spirit and scope of the invention, which is defined by the appended claims and their equivalents.

Claims (7)

1. A compound of formula (I), or a stereoisomer, tautomer or pharmaceutically acceptable salt of a compound of formula (I),
(I),
Wherein,
X 1、X2、X3、X4 and X 5 are each independently CR 4 or N;
Y is O;
T is C 1-6 alkylene, C 1-4 alkylene-O-C 1-4 alkylene or C 1-4 alkylene-NH-C 1-4 alkylene, and said T is optionally substituted with 1,2,3 or 4 substituents selected from D, F, cl, br, I, CN, NH 2、C1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkoxy C 1-4 alkoxy and C 1-4 alkylamino;
E is a bond;
ring a is of the sub-structural formula:
、、、、、、、、、、、、、、、 Or (b) And each sub-structural formula of ring a is independently optionally substituted with 1,2, 3 or 4 substituents selected from F, cl, br, OH, NH 2、NHCH3, methyl, ethyl, n-propyl, methoxy, ethoxy, isopropoxy, CF 3, hydroxymethyl and 2-hydroxyethyl;
Q is -O-、-(CH2)2O-、-CH2-、-(CH2)2-、-(CH2)3-、-(C=O)CH(OH)CH2-、-(C=O)CH(OH)-、-(C=O)-、-(C=O)CH2CH(OH)-、-(C=O)CH2-、-(C=O)(CH2)2-、-(C=O)N(CH3)-、-NH- or-NH (c=o) CH 2 -;
M is pyridinyl, pyrimidinyl, pyridazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazinyl or phenyl, and M is optionally substituted with 1, 2,3 or 4 substituents selected from D、F、Cl、CN、OH、CF3、CHCl2、CHF2、CH2F、CF3CH2、NH2、NHCH3、CH2OH、N(CH3)2、 trifluoromethoxy, 2-trifluoroethoxy, methoxy, ethoxy, isopropoxy, tert-butoxy, methyl, ethyl, n-propyl, isopropyl, phenyl, methoxymethyl, methoxyethyl, cyclopropyl and cyclohexyl;
R 1 is CN;
R 2 is H, D or C 1-4 alkyl, and said R 2 is optionally substituted with 1, 2, 3 or 4 substituents selected from F, cl, br, OH, NO 2、CN、CF3、C1-4 alkyl and C 1-4 alkoxy;
Each R 4 is independently H, D, F, cl, br, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butylmethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or t-butoxy.
2. The compound according to claim 1, wherein,
T is -CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-CH2CH(CH3)-、-CH2CH(CH3)CH2-、-CH2C(CH3)2-、-(CH2)2CH(CH3)-、-(CH2)2OCH2-、-(CH2)2NHCH2- or- (CH 2)3NHCH2) -and said T is optionally substituted by 1,2,3 or 4 substituents selected from D, F, cl, br, I, CN, NH 2, methyl, ethyl, methoxy, ethoxy, chloromethyl, fluoromethyl, methoxymethoxy and methylamino.
3. The compound according to claim 1, wherein,
R 2 is H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, ethynyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl NH 2CH2 -or NH 2(CH2)2 -, and said R 2 is optionally substituted with 1, 2, 3 or 4 substituents selected from F, cl, br, OH, CN, CF 3, methyl, methoxy, ethoxy, n-propoxy and isopropoxy.
4. A compound having the structure or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof,
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、
、、
、、
、、
、、
、、
、、
、、
、、
、、
、
、、
、、
、、
、、
、、
、、
、、
、Or (b)
。
5. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4, and a pharmaceutically acceptable adjuvant.
6. Use of a compound according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 5 for the manufacture of a medicament for the prevention or treatment of RET related diseases.
7. The use of claim 6, wherein the RET related disease is cancer, irritable bowel syndrome or pain associated with irritable bowel syndrome.
CN202110531655.1A 2020-05-18 2021-05-17 A RET inhibitor, its pharmaceutical composition and its use Active CN113683610B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020104182729 2020-05-18
CN202010418272 2020-05-18

Publications (2)

Publication Number Publication Date
CN113683610A CN113683610A (en) 2021-11-23
CN113683610B true CN113683610B (en) 2025-02-25

Family

ID=78576338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110531655.1A Active CN113683610B (en) 2020-05-18 2021-05-17 A RET inhibitor, its pharmaceutical composition and its use

Country Status (1)

Country Link
CN (1) CN113683610B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (en) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177786A (en) * 2016-10-10 2019-08-27 阿雷生物药品公司 Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor
WO2020064009A1 (en) * 2018-09-30 2020-04-02 北京志健金瑞生物医药科技有限公司 Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN112368283A (en) * 2019-05-14 2021-02-12 上海翰森生物医药科技有限公司 Bicyclic derivative-containing inhibitor, preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177786A (en) * 2016-10-10 2019-08-27 阿雷生物药品公司 Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor
WO2020064009A1 (en) * 2018-09-30 2020-04-02 北京志健金瑞生物医药科技有限公司 Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN112368283A (en) * 2019-05-14 2021-02-12 上海翰森生物医药科技有限公司 Bicyclic derivative-containing inhibitor, preparation method and application thereof

Also Published As

Publication number Publication date
CN113683610A (en) 2021-11-23

Similar Documents

Publication Publication Date Title
CN113683610B (en) A RET inhibitor, its pharmaceutical composition and its use
CN113683611B (en) New RET inhibitors, pharmaceutical compositions and uses thereof
CN112574235B (en) A RET inhibitor, its pharmaceutical composition and its use
JP7457709B2 (en) RET inhibitors, pharmaceutical compositions, and uses thereof
CN113527290B (en) RET inhibitor, pharmaceutical composition and application thereof
CN113527291B (en) RET inhibitor, pharmaceutical composition thereof and application thereof
CN112442050B (en) A RET inhibitor, its pharmaceutical composition and use thereof
JP7457708B2 (en) RET inhibitors, pharmaceutical compositions and uses thereof
CN113527292B (en) RET inhibitor, pharmaceutical composition and application thereof
JP6133291B2 (en) Pyrazolo [3,4-c] pyridine compounds and methods of use
CN113620944B (en) Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof
CN113620945B (en) RET inhibitor, pharmaceutical composition thereof and application of RET inhibitor in medicines
KR20140024203A (en) Pyridone and aza-pyridone compounds and methods of use
RU2694254C1 (en) Nitrogen-containing heterocyclic derivatives and use thereof in medicinal preparations
CN112574236B (en) RET inhibitor, pharmaceutical composition and application thereof
CN117396208A (en) Small molecule degraders of cyclin-dependent kinase 4/6 (CDK4/6) and IKZF2 (HELIOS) and methods of using them
CN116836167B (en) Imidazo [1,2-a ] pyrazine or pyrazolo [1,5-a ] pyrimidine derivatives and uses thereof
CN117003754B (en) Pyrrolo [2,3-d ] pyrimidine or pyrazolo [3,4-d ] pyrimidine derivatives and uses thereof
CN115894482A (en) RET inhibitor and preparation method and application thereof
CN105461709A (en) Substituted carbamide derivative and applications thereof in drugs
HK1193807A (en) Pyrazolo[3,4-c]pyridine compounds and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd.

GR01 Patent grant
GR01 Patent grant